[{"text": "Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Aclaris Therapeutics, Inc. Tue, Jan 7, 2025, 12:30 AM 1 min read In This Article: ACRS -3.23% Aclaris Therapeutics, Inc. WAYNE, Pa., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS) (the \u201cCompany\u201d or \u201cAclaris\u201d), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that effective January 2, 2025, the Compensation Committee of Aclaris\u2019 Board of Directors (the Committee)\u00a0granted nonstatutory stock options to purchase an aggregate of 215,000 shares of its common stock and 61,000 restricted stock units to 1 new employee under the Aclaris Therapeutics, Inc. 2024 Inducement Plan (the \u201c2024 Inducement Plan\u201d). \u00a0The stock options and restricted stock units were granted as inducements material to the new employee becoming an employee of Aclaris in accordance with NASDAQ Listing Rule 5635(c)(4). The 2024 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Aclaris (or following a bona fide period of non-employment), as an inducement material to such individuals\u2019 entering into employment with Aclaris, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules. The options have an exercise price of $2.48 per share, which is equal to the closing price of Aclaris\u2019 common stock on January 2, 2025. Each option and restricted stock unit award will vest, and become exercisable (as applicable), as to twenty-five percent of the shares on each of the first, second, third, and fourth anniversaries of the grant date,\u00a0subject to the employee's continued employment with Aclaris on such vesting dates. The options and restricted stock unit awards are subject to the terms and conditions of Aclaris' 2024 Inducement Plan, and the terms and conditions of a stock option agreement or restricted stock unit award agreement, as applicable, covering the grant. Aclaris Therapeutics Contact: investors@aclaristx.com View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "ACRS", "date": "2025-01-07T00:30:00", "sentiment": {"score": -0.000797707587480545, "confidence": 0.023514090105891228, "probabilities": {"positive": 0.022716382518410683, "negative": 0.023514090105891228, "neutral": 0.9537695050239563}}, "embedding": [-0.16229666769504547, 0.0075318338349461555, -0.008439663797616959, -0.03873109444975853, -0.13606438040733337, 0.07984461635351181, 0.07037892937660217, 0.17684012651443481, 0.13183622062206268, 0.0782470628619194, 0.06989731639623642, 0.03792624920606613, -0.007017362397164106, 0.057683538645505905, -0.10842914879322052, 0.04254972189664841, 0.02582802250981331, 0.005459463223814964, -0.21288248896598816, 0.012139812111854553, -0.00533086434006691, -0.10937653481960297, -0.07671895623207092, -0.09525662660598755, 0.05554024130105972, -0.1600109040737152, -0.09036210179328918, 0.03258243948221207, -0.044828977435827255, -0.0284353569149971, 0.01423052977770567, 0.05976073071360588, 0.07402729988098145, -0.07869260013103485, -0.00753377377986908, -0.008919181302189827, -0.12641116976737976, 0.03943631052970886, 0.03780302032828331, 0.06359266489744186, -0.005210623610764742, -0.01703736186027527, -0.02088191732764244, 0.09545442461967468, -0.07921978831291199, -0.08940421044826508, -0.05520357936620712, 0.030595257878303528, 0.025203777477145195, 0.1393631100654602, -0.06965259462594986, 0.05005985498428345, 0.040371768176555634, 0.12424755096435547, -0.16298410296440125, -0.0854303315281868, -0.17014911770820618, -0.11495828628540039, -0.041381850838661194, 0.04722943529486656, -0.008603096008300781, -0.09497809410095215, 0.00455726683139801, 0.06563717126846313, 0.01904497668147087, -0.009026790037751198, 0.01747317984700203, -0.03661017864942551, -0.023757420480251312, 0.05116824060678482, 0.15443851053714752, -0.08468596637248993, -0.053198233246803284, 0.007383162155747414, 0.040970329195261, 0.19699782133102417, 0.025903809815645218, 0.06892292946577072, 0.0789748877286911, -0.24089254438877106, 0.009153658524155617, 0.10363009572029114, 0.0071657756343483925, -0.09242361783981323, -0.03663143888115883, -0.024694805964827538, 0.01637456938624382, 0.10619550943374634, 0.10416928678750992, 0.08948234468698502, 0.07048653066158295, -0.02083681896328926, 0.018959028646349907, -0.1004091203212738, 0.0799325555562973, -0.07636190950870514, -0.011583179235458374, -0.05300239101052284, -0.04713093116879463, 0.053367529064416885, 0.00785486027598381, -0.0131231052801013, -0.09895329177379608, -0.023170901462435722, -0.07034403085708618, -0.13462764024734497, -0.009284429252147675, -0.12663841247558594, 0.04547552019357681, 0.03631891310214996, -0.14847484230995178, 0.04714837670326233, -0.04239950329065323, -0.08266530185937881, -0.11543569713830948, 0.18746840953826904, -0.014019209891557693, -0.03743269294500351, 0.1764223277568817, -0.11477522552013397, 0.09597018361091614, 0.00854475237429142, -0.10681967437267303, -0.02992767095565796, -0.004723532125353813, -0.06842388212680817, -0.18652087450027466, 8.21934008896157e-33, -0.042157016694545746, -0.04664414003491402, -0.024229057133197784, 0.019465642049908638, 0.04832865297794342, -0.04430484026670456, 0.015229489654302597, 0.009421242401003838, -0.07748490571975708, 0.04072697088122368, -0.16527687013149261, 0.049455426633358, 0.07761745899915695, 0.01168860588222742, 0.058835722506046295, -0.03333768621087074, 0.11964033544063568, 0.10623300075531006, 0.04754863679409027, -0.013780774548649788, 0.10512425005435944, 0.12184752523899078, -0.04306422173976898, 0.1458471715450287, 0.028354790061712265, -0.005798928439617157, -0.06529491394758224, -0.014389251358807087, -0.07603225857019424, 0.0169675312936306, 0.0254664309322834, 0.09873189777135849, 0.03085300140082836, -0.07063929736614227, 0.04991838335990906, 0.032653771340847015, -0.1032729297876358, -0.03380788117647171, 0.07879502326250076, -0.0011744932271540165, 0.07654495537281036, 0.032211557030677795, 0.017580628395080566, -0.11254899203777313, 0.02519848197698593, -0.06215517222881317, -0.0729280337691307, 0.08614568412303925, 0.039248988032341, 0.09452393651008606, 0.054030947387218475, 0.07316119968891144, 0.0031360555440187454, -0.09700580686330795, -0.025336263701319695, -0.006888176314532757, -0.26713019609451294, 0.05795662850141525, 0.07601034641265869, 0.06463930755853653, 0.01092366874217987, 0.12493724375963211, 0.007554655894637108, 0.10543651133775711, -0.22248142957687378, 0.0797525942325592, -0.07827559858560562, -0.15103477239608765, 0.10680029541254044, 0.045363955199718475, -0.06124892458319664, 0.08896999061107635, 0.05833789333701134, -0.008040854707360268, 0.054967910051345825, -0.06157711148262024, 0.1165708601474762, 0.09046755731105804, -0.007547980640083551, -0.01071158703416586, -0.016212623566389084, -0.010642146691679955, 0.0033534709364175797, 0.11627275496721268, 0.02907356061041355, -0.07188381254673004, 0.029467452317476273, 0.15323902666568756, -0.0672757551074028, -0.08872577548027039, 0.21347704529762268, -0.01528170332312584, -0.09376886487007141, 0.14124198257923126, 0.11281142383813858, -9.368776668762005e-33, 0.023576997220516205, -0.0790618360042572, -0.0407424122095108, -0.19907626509666443, -0.0233050175011158, 0.1275017261505127, 0.0789676308631897, 0.007112068124115467, -0.023421458899974823, -0.0665970891714096, 0.03836429491639137, 0.1006348580121994, 0.02987610548734665, -0.0763230249285698, -0.1717480719089508, 0.03894320875406265, -0.05783325806260109, -0.017276592552661896, -0.01597670651972294, 0.09762066602706909, -0.07106354832649231, 0.19351661205291748, 0.04901839792728424, 0.08889417350292206, 0.14869001507759094, 0.07385390996932983, -0.04379384219646454, 0.15824443101882935, -0.003445848822593689, 0.021991269662976265, -0.12111072242259979, -0.028815697878599167, -0.32375121116638184, 0.024247394874691963, 0.02703101933002472, -0.2176017463207245, 0.12586814165115356, -0.09562854468822479, -0.0001995610073208809, 0.06382234394550323, 0.09793547540903091, -0.05659825727343559, 0.11319375783205032, 0.18560890853405, 0.12687042355537415, -0.06684183329343796, 0.11328985542058945, -0.19254694879055023, 0.10870903730392456, -0.08953724801540375, -0.01968449354171753, -0.03439417481422424, 0.1450248658657074, 0.09104554355144501, 0.08577559888362885, 0.02611745521426201, 0.06334054470062256, -0.151070699095726, 0.04395285248756409, -0.08008817583322525, 0.11711329221725464, 0.07676646113395691, 0.018169183284044266, 0.020780209451913834, 0.09681642055511475, -0.06613472104072571, -0.1111191064119339, -0.05571187287569046, -0.03912859410047531, -0.046578697860240936, -0.026312418282032013, -0.09790042042732239, 0.029595889151096344, -0.19414493441581726, 0.0913948342204094, 0.11202903091907501, 0.09625588357448578, -0.1674286127090454, -0.18167467415332794, 0.012224027886986732, -0.158238485455513, -0.007296981755644083, 0.022945068776607513, 0.1249026209115982, 0.000651857815682888, 0.027846114709973335, 0.08148522675037384, 0.02340451255440712, 0.05041089281439781, 0.05331471934914589, -0.07813024520874023, -0.07202214002609253, 0.03517546504735947, 0.0672144740819931, -0.06449833512306213, -1.0065541289350222e-07, 0.03149433806538582, 0.07386700809001923, -0.022831637412309647, -0.06944441050291061, 0.1250590980052948, -0.027324097231030464, -0.1255244016647339, -0.04901226609945297, 0.013259679079055786, 0.05407494679093361, -0.0139623386785388, 0.1977507621049881, -0.04354000464081764, -0.0077925557270646095, -0.10057400912046432, -0.05613362416625023, -0.06680324673652649, -0.02787116914987564, -0.03456484526395798, -0.05965902656316757, -0.19984877109527588, -0.014618175104260445, -0.02335408888757229, 0.008001341484487057, -0.04288347065448761, 0.013024117797613144, 0.07222311198711395, -0.05462726950645447, 0.009079203009605408, 0.09155485033988953, -0.05521086975932121, 0.01792360097169876, 0.04498744755983353, -0.013172092847526073, -0.054703667759895325, -0.06581640243530273, 0.027687784284353256, 0.03707079589366913, -0.027147326618433, -0.026961801573634148, 0.06167607009410858, 0.00878523662686348, 0.020184911787509918, 0.03375677764415741, 0.06386758387088776, -0.059537868946790695, -0.19037407636642456, -0.11542049795389175, -0.014850647188723087, -0.14099934697151184, 0.0844539999961853, 0.013233937323093414, -0.03722234070301056, 0.010821196250617504, 0.08830149471759796, -0.006423202343285084, -0.02893306314945221, -0.08911427855491638, -0.01992649771273136, -0.11146020144224167, -0.040222179144620895, -0.03860306367278099, 0.0004870183765888214, 0.0798066109418869], "changes": {"1wk": -1.9762827225969646}}, {"text": "PREMIUM HC Wainwright Upgrades Aclaris Therapeutics to Buy From Neutral, $20 Price Target MT Newswires Mon, Dec 23, 2024, 3:04 PM In This Article: ACRS -3.23% Aclaris Therapeutics (ACRS) has an average rating of buy and mean price target of $10, according to PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "ACRS", "date": "2024-12-23T15:04:25", "sentiment": {"score": 0.03748239204287529, "confidence": 0.05127903074026108, "probabilities": {"positive": 0.05127903074026108, "negative": 0.013796638697385788, "neutral": 0.9349243640899658}}, "embedding": [-0.2134736180305481, -0.12349185347557068, -0.1393214762210846, 0.06061164289712906, 0.07803639769554138, -0.00788324698805809, 0.0323675312101841, 0.29997551441192627, 0.07267190515995026, 0.060951124876737595, 0.1337818056344986, 0.01356801949441433, 0.03035091422498226, 0.05032551661133766, -0.009401168674230576, 0.08925970643758774, 0.18927203118801117, -0.17896638810634613, -0.07177295535802841, -0.061101701110601425, -0.33940136432647705, 0.05770443007349968, -0.07019848376512527, 0.022066624835133553, 0.13990409672260284, -0.16643090546131134, -0.181674063205719, -0.15364490449428558, -0.03130641207098961, -0.030800359323620796, 0.008929847739636898, -0.06319917738437653, 0.13673155009746552, 0.009324419312179089, 0.011465171352028847, -0.12170537561178207, -0.05121598765254021, -0.04810463637113571, 0.007924200966954231, 0.139378160238266, 0.1179857924580574, 0.0451267808675766, -0.21084831655025482, 0.02100069634616375, -0.15602542459964752, -0.16156360507011414, -0.12296316772699356, 0.15901553630828857, 0.1815483421087265, 0.2768433690071106, -0.0477728545665741, -0.0074893101118505, 0.07563856244087219, -0.10667263716459274, -0.2634325623512268, 0.010699869133532047, -0.15461266040802002, -0.10706310719251633, 0.007167636416852474, 0.0020983207505196333, -0.11662948131561279, -0.1347384750843048, -0.07954596728086472, 0.06865877658128738, -0.10820085555315018, 0.0575549453496933, 0.03693319484591484, -0.0008034619968384504, 0.07007378339767456, -0.023822106420993805, 0.04352441057562828, 0.001965791452676058, 0.2395647168159485, -0.10068923234939575, 0.20671378076076508, 0.04168939217925072, 0.11410725861787796, -0.14321482181549072, 0.015196742489933968, -0.01473280694335699, -0.0494510680437088, -0.05308153107762337, -0.021213553845882416, -0.06860148906707764, 0.08288449048995972, -0.13324026763439178, 0.16617189347743988, 0.07757765799760818, -0.0010963052045553923, 0.08943282812833786, 0.06764159351587296, -0.03283264487981796, -0.07091514766216278, -0.07438219338655472, -0.15113623440265656, 0.09210468083620071, -0.02327776327729225, -0.07917346060276031, -0.01441196445375681, -0.05463857203722, 0.06134132668375969, 0.06493794918060303, -0.03420872241258621, -0.09031360596418381, -0.11642580479383469, -0.21520857512950897, -0.08895773440599442, 0.21615102887153625, 0.11877034604549408, 0.13537204265594482, -0.0817653238773346, 0.0046860091388225555, -0.008566753007471561, -0.18830466270446777, -0.04425714910030365, 0.16769041121006012, -0.11494757980108261, -0.12370168417692184, 0.17025236785411835, -0.04221297800540924, 0.060332041233778, -0.07249801605939865, -0.1421520709991455, 0.11437077075242996, 0.005872063338756561, -0.13519318401813507, -0.11965662240982056, 8.963671928109874e-33, -0.20955541729927063, 0.16216591000556946, -0.06689953058958054, -0.15574991703033447, -0.12284639477729797, 0.007174140308052301, 0.013307253830134869, 0.100911945104599, -0.06856858730316162, -0.09572277218103409, -0.09212903678417206, 0.11403977125883102, -0.020039206370711327, 0.12358655035495758, -0.07143784314393997, -0.21875540912151337, 0.019968004897236824, 0.062404122203588486, 0.022594217211008072, 0.013181554153561592, -0.058131128549575806, 0.01101278979331255, -0.08316468447446823, 0.04569011181592941, -0.08408790081739426, 0.10291243344545364, 0.15980201959609985, 0.10173948854207993, 0.06824031472206116, -0.005130273289978504, -0.11380397528409958, 0.1504552662372589, 0.11695649474859238, 0.07744553685188293, 0.004646428860723972, 0.1760915070772171, -0.11638146638870239, -0.06791383773088455, -0.0008788742707110941, -0.09403438866138458, 0.0423288531601429, 0.1713576465845108, -0.05560574680566788, -0.043995849788188934, 0.1533820778131485, -0.0725155919790268, -0.18035155534744263, -0.10484831780195236, -0.06083895266056061, -0.11617843806743622, -0.08393535763025284, 0.16441306471824646, -0.08077871054410934, 0.11277658492326736, -0.06640613079071045, -0.0768963024020195, -0.24110819399356842, -0.048736944794654846, 0.07314520329236984, -0.07116613537073135, 0.1681448221206665, 0.02678884007036686, 0.04942118003964424, -0.15536577999591827, -0.1947164237499237, 0.08990863710641861, -0.1436954140663147, -0.17773687839508057, -0.11196654289960861, 0.20553958415985107, 0.09618008881807327, 0.18682746589183807, 0.07709295302629471, 0.07750768214464188, 0.11575735360383987, 0.05367005988955498, -0.03648676350712776, 0.14066651463508606, 0.1878025233745575, 0.014877649955451488, -0.0767037644982338, 0.02782626636326313, 0.15588809549808502, 0.1755078136920929, 0.052163779735565186, -0.14989706873893738, -0.09396415948867798, 0.16460834443569183, -0.04143236577510834, 0.04186267778277397, 0.22148863971233368, 0.07617205381393433, -0.22772203385829926, 0.13252130150794983, 0.11245168000459671, -1.2548976717891884e-32, 0.026556918397545815, -0.035329122096300125, 0.11823146790266037, -0.04432186484336853, -0.1645275503396988, 0.08648165315389633, -0.16546453535556793, 0.26896148920059204, 0.23587936162948608, 0.1318116933107376, 0.03536421060562134, 0.22527849674224854, -0.10551709681749344, 0.029978211969137192, 0.0014964448055252433, 0.034059152007102966, 0.04630514234304428, 0.018025701865553856, 0.05803384631872177, 0.04396825656294823, -0.10202186554670334, 0.17498430609703064, 0.07288402318954468, 0.12057474255561829, 0.11085841059684753, 0.010536798276007175, 0.025113224983215332, 0.0764331966638565, 0.035205695778131485, 0.040672481060028076, -0.0651908591389656, -0.0011200058506801724, -0.16242654621601105, -0.05096177011728287, -0.10231515020132065, 0.005405487958341837, 0.14184440672397614, 0.030423665419220924, -0.03108207695186138, -0.027772419154644012, 0.13216133415699005, -0.09722728282213211, 0.07821092754602432, -0.03985270485281944, 0.16861902177333832, -0.06084089353680611, 0.12453003972768784, -0.06647206097841263, 0.03722788766026497, -0.08117640018463135, -7.955628825584427e-05, -0.07435405999422073, 0.11315795034170151, 0.04057687893509865, -0.13224183022975922, 0.00752520514652133, 0.07039915770292282, -0.100435771048069, 0.039572715759277344, -0.2281133085489273, 0.07416382431983948, 0.22161820530891418, -0.1278570294380188, -0.041046567261219025, -0.0771951824426651, 0.04724513366818428, 0.06928836554288864, -0.15541507303714752, -0.04007502645254135, 0.00022692953643854707, 0.056392405182123184, 0.019687356427311897, 2.9998815080034547e-05, -0.21859821677207947, 0.028515087440609932, 0.07056862860918045, 0.0536065436899662, -0.039220765233039856, -0.16253173351287842, -0.12318956851959229, -0.04996117204427719, -0.0908723846077919, 0.06260441243648529, 0.03419455513358116, -0.030075587332248688, -0.02838459424674511, 0.0682651549577713, -0.045708417892456055, -0.16466450691223145, 0.08264672756195068, -0.16482004523277283, -0.03251538798213005, -0.01157230231910944, -0.04719437286257744, 4.771048770635389e-05, -1.0072417211404172e-07, 0.006470746826380491, 0.18643975257873535, -0.13517031073570251, 0.047836728394031525, 0.03031923808157444, 0.15142150223255157, -0.1548164039850235, -0.03354734182357788, -0.1003953069448471, 0.14485430717468262, -0.050244610756635666, -0.0008554549422115088, -0.009679700247943401, -0.03702034056186676, -0.14623206853866577, -0.09365704655647278, 0.01166859082877636, 0.0990033894777298, 0.08328898251056671, -0.03925245255231857, -0.16397973895072937, 0.16858169436454773, 0.11445155739784241, 0.04061490669846535, -0.0329008512198925, 0.18364866077899933, 0.10943479835987091, -0.05647924542427063, 0.0793042927980423, -0.04298952594399452, -0.053172361105680466, 0.11306650936603546, 0.00882651749998331, 0.06754200905561447, 0.16034072637557983, -0.08124673366546631, -0.024942373856902122, 0.028377676382660866, -0.04785729572176933, -0.02800634689629078, 0.021144742146134377, -0.05581766739487648, -0.20231623947620392, 0.021590163931250572, 0.062026623636484146, -0.04386337846517563, -0.0809510350227356, -0.20285513997077942, 0.02420356310904026, -0.09702856093645096, 0.2354802042245865, -0.10121064633131027, 0.0177388247102499, -0.11748278886079788, 0.06108488515019417, -0.10992700606584549, -0.008858234621584415, -0.262104332447052, -0.1398431956768036, 0.0986252874135971, 0.0657147616147995, -0.264487087726593, -0.01747213862836361, 0.13087661564350128], "changes": {"1wk": -5.536334948887266, "1mo": -10.034608641691454}}, {"text": "PREMIUM Aclaris Therapeutics Files Statement for Share Resale by Stockholders; Stock Rises After Hours MT Newswires Fri, Dec 20, 2024, 1:24 AM In This Article: ACRS -3.23% Aclaris Therapeutics (ACRS) filed a registration statement with the US Securities and Exchange Commi PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "ACRS", "date": "2024-12-20T01:24:11", "sentiment": {"score": 0.05505913496017456, "confidence": 0.06702016294002533, "probabilities": {"positive": 0.06702016294002533, "negative": 0.011961027979850769, "neutral": 0.9210188388824463}}, "embedding": [-0.24476799368858337, -0.10602693259716034, -0.07177814841270447, 0.15942849218845367, 0.07510681450366974, -0.0226066242903471, 0.07228077948093414, 0.17247316241264343, 0.13890156149864197, 0.013664387166500092, 0.11410053819417953, 0.1503760665655136, -0.04736176133155823, 0.031369399279356, -0.03818853944540024, -0.0117306774482131, -0.044912904500961304, -0.09388945996761322, -0.07020547986030579, -0.03434609994292259, -0.16516666114330292, -0.07372599840164185, -0.07170671969652176, 0.07859139889478683, 0.14750880002975464, -0.11879357695579529, -0.1851634681224823, 0.009809751063585281, -0.005337054841220379, -0.024752411991357803, -0.022556541487574577, -0.0654478594660759, 0.2376655638217926, 0.01208885945379734, -0.001693042227998376, -0.04812551289796829, -0.01972404308617115, -0.09473755210638046, 0.08165109902620316, 0.06679724156856537, 0.0849459171295166, -0.14624883234500885, -0.07818005234003067, 0.12462181597948074, -0.10302340984344482, -0.061687927693128586, -0.12140673398971558, 0.10359211266040802, 0.04943934455513954, 0.25478941202163696, -0.13557745516300201, 0.006733966525644064, 0.06137114763259888, -0.12122923880815506, -0.16390125453472137, 0.024623345583677292, -0.1920643150806427, -0.16491733491420746, -0.003443235531449318, -0.05568152293562889, -0.041928134858608246, -0.08945120871067047, -0.06018368899822235, 0.18014869093894958, -0.06545867770910263, 0.1405615508556366, 0.09555123001337051, 0.1855286955833435, 0.024819348007440567, -0.06318365037441254, 0.045866936445236206, -0.0034964329097419977, 0.003182990476489067, 0.11553816497325897, 0.01971205696463585, 0.06918554753065109, 0.06158285215497017, -0.022422941401600838, 0.05204363912343979, -0.09714196622371674, 0.009111534804105759, 0.03325670212507248, 0.08204145729541779, -0.037623994052410126, 0.0024364565033465624, -0.056278716772794724, 0.09761615842580795, -0.007622451055794954, -0.03813330829143524, 0.03254314884543419, 0.06106897443532944, -0.0397397056221962, -0.03860848397016525, 0.04023153707385063, -0.13663838803768158, -0.018860677257180214, -0.09269308298826218, -0.10313162952661514, -0.09407328069210052, -0.0019807429052889347, 0.035245560109615326, 0.1553938239812851, 0.0012836098903790116, 0.006767089944332838, -0.09784941375255585, -0.26510098576545715, -0.04841463640332222, 0.12211918085813522, 0.03003774583339691, 0.12609270215034485, 0.012418583035469055, 0.0587623156607151, -0.011292967945337296, -0.20412981510162354, -0.06646284461021423, 0.20552009344100952, -0.25651806592941284, -0.02152409963309765, 0.1679610162973404, -0.056531745940446854, 0.1041509360074997, 0.05194462090730667, -0.25894418358802795, -0.01682107336819172, 0.11062216013669968, -0.11116921901702881, -0.021177634596824646, 1.4156181654629226e-32, -0.21089300513267517, 0.10008163750171661, 0.030591759830713272, 0.06438883394002914, 0.04808014631271362, -0.0181476678699255, -0.0077627175487577915, -0.005605578422546387, -0.16843193769454956, -0.03229360654950142, -0.1305442452430725, 0.10968714952468872, -0.03887886181473732, 0.04236660152673721, -0.13017098605632782, -0.15142296254634857, 0.0271301306784153, 0.09736984968185425, 0.0985698401927948, -0.02852877415716648, 0.04246702790260315, -0.0181135144084692, -0.07102865725755692, 0.0717787891626358, -0.05632264167070389, 0.052655767649412155, 0.07709557563066483, 0.004934437572956085, 0.010759027674794197, 0.008324229158461094, 0.026971206068992615, 0.05321156606078148, 0.024576503783464432, -0.047372862696647644, 0.13968583941459656, 0.183562234044075, -0.025732969865202904, -0.05832566320896149, 0.06119687110185623, -0.010684228502213955, 0.1152949184179306, 0.05673253536224365, -0.13289394974708557, -0.042567867785692215, 0.04001529514789581, -0.00845337100327015, -0.19587798416614532, -0.030126502737402916, 0.059871919453144073, -0.049992434680461884, -0.03236844390630722, 0.1167227178812027, -0.075058713555336, -0.0064831809140741825, 0.00479111447930336, 0.04899929091334343, -0.30761611461639404, -0.12983717024326324, 0.025255385786294937, -0.12023095041513443, 0.23838189244270325, 0.05429650843143463, 0.023871487006545067, -0.1115514487028122, -0.29769861698150635, 0.04198969155550003, -0.06397666782140732, -0.11039306968450546, -0.10444028675556183, 0.21329019963741302, 0.12628060579299927, 0.06936375796794891, 0.01071933563798666, 0.06369298696517944, 0.07154588401317596, 0.08211058378219604, 0.011354518122971058, 0.029977086931467056, 0.08716917783021927, 0.05077582597732544, 0.04679643362760544, -0.04162927716970444, 0.17155376076698303, 0.2160264104604721, -0.030428817495703697, 0.004324150737375021, -0.02815219946205616, 0.12285041064023972, -0.006577410735189915, -0.043810922652482986, 0.1718471795320511, 0.006143700331449509, -0.08484907448291779, 0.15834203362464905, -0.028657613322138786, -1.67217259932897e-32, 0.13118910789489746, -0.14371046423912048, 0.048412028700113297, -0.1351194679737091, -0.17579849064350128, 0.025610337033867836, -0.07146862894296646, 0.3243784010410309, 0.12207205593585968, 0.049233123660087585, 0.11966580152511597, 0.12964704632759094, -0.09311796724796295, -0.0682612806558609, 0.012815339490771294, 0.05610070377588272, 0.0875597819685936, -0.03898568078875542, -0.08120191842317581, 0.057308994233608246, -0.13258787989616394, 0.08401548862457275, 0.06967838853597641, 0.1359228789806366, 0.12782523036003113, 0.01616343855857849, 0.05213638022542, 0.12480979412794113, -0.0020392541773617268, -0.019540175795555115, -0.08894119411706924, -0.10463305562734604, -0.21275347471237183, -0.03159186616539955, -0.11278413236141205, -0.1272771805524826, 0.10058929026126862, -0.001671023084782064, -0.07068324834108353, 0.0752047747373581, 0.1363617181777954, -0.07505307346582413, 0.051747191697359085, 0.09475714713335037, 0.13506487011909485, -0.03425416350364685, 0.134902685880661, -0.0728222131729126, 0.15838876366615295, -0.0700213611125946, -0.06637173146009445, -0.10517781972885132, 0.1723487824201584, 0.05369848012924194, -0.022524971514940262, 0.10249290615320206, 0.03337951377034187, -0.14761073887348175, -0.0780496895313263, -0.165440171957016, 0.09154582768678665, 0.13878612220287323, -0.15718483924865723, -0.0008362702210433781, -0.0422036275267601, -0.07928360253572464, -0.03773830831050873, -0.11250961571931839, -0.04535116255283356, -0.014684495516121387, 0.14599868655204773, -0.04850558191537857, -0.20263980329036713, -0.2574314773082733, 0.01091499999165535, 0.14894452691078186, 0.029564641416072845, -0.06675892323255539, -0.24662518501281738, -0.008248049765825272, 0.005230767652392387, -0.014762762933969498, -0.024228500202298164, 0.19179269671440125, -0.19684945046901703, 0.04185503348708153, 0.12029042094945908, -0.09085102379322052, -0.09471798688173294, 0.04800384119153023, -0.18182958662509918, -0.10612872987985611, -0.07134843617677689, 0.03408490866422653, -0.04426396265625954, -1.0058796817702387e-07, -0.05205908417701721, 0.08015994727611542, -0.00024949738872237504, -0.062019288539886475, 0.08389036357402802, 0.11444201320409775, -0.025715649127960205, -0.05552732199430466, -0.0027551748789846897, 0.07979761064052582, -0.0844346135854721, 0.05046135187149048, -0.010129066184163094, -0.11835911124944687, -0.06448862701654434, -0.10858941078186035, -0.03560594841837883, 0.12678351998329163, 0.010095231235027313, -0.1317663937807083, -0.09859532117843628, 0.12229104340076447, 0.29334670305252075, -0.06550028175115585, -0.02600421942770481, 0.10048088431358337, 0.07622648775577545, -0.05665620043873787, 0.0473814494907856, -0.004766442812979221, -0.09369860589504242, 0.0943693071603775, 0.07925347238779068, -0.04668626934289932, 0.06303383409976959, -0.031593047082424164, 0.11082953214645386, 0.012634376995265484, -0.0625806376338005, -0.08920256793498993, -0.053753361105918884, -0.014980405569076538, 0.04877835512161255, 0.10393308848142624, -0.02244136855006218, -0.059956375509500504, -0.0634247213602066, -0.09556315839290619, 0.0998820886015892, -0.15051305294036865, 0.17680276930332184, -0.11199893802404404, 0.06048930436372757, 0.019204774871468544, -0.017661388963460922, -0.02055884338915348, -0.06089646369218826, -0.025661040097475052, -0.1627197116613388, 0.02148417755961418, 0.06843998283147812, -0.18306490778923035, -0.021972008049488068, 0.08604806661605835], "changes": {"1wk": 5.2346563871821346, "1mo": -7.220218377648491}}, {"text": "Aclaris Therapeutics (ACRS) Reports Q3 Loss, Misses Revenue Estimates Zacks Equity Research Wed, Nov 6, 2024, 4:05 PM 3 min read In This Article: ACRS -3.23% Aclaris Therapeutics (ACRS) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to loss of $0.41 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -37.50%. A quarter ago, it was expected that this specialty pharmaceutical company would post a loss of $0.19 per share when it actually produced a loss of $0.15, delivering a surprise of 21.05%. Over the last four quarters, the company has surpassed consensus EPS estimates three times. Aclaris , which belongs to the Zacks Medical - Drugs industry, posted revenues of $4.35 million for the quarter ended September 2024, missing the Zacks Consensus Estimate by 47.68%. This compares to year-ago revenues of $9.28 million. The company has topped consensus revenue estimates three times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Aclaris shares have added about 111.4% since the beginning of the year versus the S&P 500's gain of 21.2%. What's Next for Aclaris? While Aclaris has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Aclaris: mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.15 on $1.82 million in revenues for the coming quarter and -$0.65 on $15.28 million in revenues for the current fiscal year. Story Continues Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Drugs is currently in the top 37% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. One other stock from the same industry, VAXART, INC. (VXRT), is yet to report results for the quarter ended September 2024. This company is expected to post quarterly loss of $0.10 per share in its upcoming report, which represents a year-over-year change of +9.1%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. VAXART, INC.'s revenues are expected to be $2.89 million, up 37.6% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Aclaris Therapeutics, Inc. (ACRS) : Free Stock Analysis Report VAXART, INC. (VXRT) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "ACRS", "date": "2024-11-06T16:05:07", "sentiment": {"score": -0.15296570956707, "confidence": 0.2790221571922302, "probabilities": {"positive": 0.12605644762516022, "negative": 0.2790221571922302, "neutral": 0.594921350479126}}, "embedding": [-0.20174086093902588, 0.0026191743090748787, -0.06362788379192352, 0.10019105672836304, -0.040222302079200745, -0.034177135676145554, -0.04343791678547859, 0.2343544065952301, 0.25572165846824646, 0.09537568688392639, -0.06429335474967957, 0.1451036036014557, -0.009800607338547707, -0.031400859355926514, -0.17867861688137054, -0.0052238330245018005, 0.059975072741508484, -0.03544551134109497, -0.18366868793964386, 0.010824142023921013, -0.09440538287162781, -0.03878827020525932, 0.03670595586299896, 0.03188926354050636, 0.12033353745937347, -0.022084496915340424, -0.1518198549747467, 0.02636473812162876, -0.13760223984718323, -0.14890366792678833, -0.017511336132884026, 0.08149927854537964, 0.1279226839542389, -0.06625212728977203, -0.05318393185734749, -0.046776846051216125, -0.016852444037795067, 0.059127144515514374, 0.17766228318214417, 0.040023647248744965, -0.05508578196167946, 0.04118065536022186, -0.13475185632705688, 0.03197229281067848, -0.12880127131938934, -0.23563404381275177, -0.10394546389579773, 0.01559714786708355, 0.05711669102311134, 0.1632004678249359, -0.20034831762313843, -0.04874759167432785, 0.08549108356237411, 0.05116039514541626, -0.17282672226428986, 0.031773023307323456, -0.16014954447746277, -0.12876376509666443, 0.027433715760707855, 0.0923900231719017, -0.0034893560223281384, -0.0163450688123703, 0.0031990427523851395, 0.11901496350765228, 0.05853452906012535, 0.0008879173547029495, 0.06613205373287201, 0.012135900557041168, -0.08984152972698212, 0.08212514966726303, 0.12832126021385193, -0.06383923441171646, -0.031271081417798996, -0.03892030566930771, 0.009024352766573429, 0.005349842831492424, 0.05495934188365936, 0.017318226397037506, -0.0002945335581898689, -0.043443161994218826, 0.0773853063583374, -0.0025619985535740852, -0.08886279165744781, -0.05217135697603226, 0.03402481600642204, -0.05449778214097023, 0.15718147158622742, 0.1207207515835762, 0.04728265479207039, 0.10218508541584015, -0.06570453941822052, -0.01014157384634018, -0.026827450841665268, -0.06472542136907578, 0.09796401858329773, 0.06311702728271484, 0.023402541875839233, -0.12748922407627106, 0.0250152125954628, 0.03729963302612305, 0.11192312836647034, 0.1522807478904724, -0.016575245186686516, -0.16336819529533386, 0.015359598211944103, -0.17312462627887726, 0.0828370675444603, -0.033932190388441086, 0.052996017038822174, 0.09846711903810501, -0.08131204545497894, 0.10068519413471222, -0.1807435005903244, -0.08733470737934113, -0.029107820242643356, 0.09434857219457626, -0.04595613852143288, 0.09096992015838623, 0.0981091558933258, 0.09654834121465683, 0.06122374162077904, 0.07152780890464783, -0.12889713048934937, 0.0527612566947937, 0.11126412451267242, 0.039863936603069305, -0.1841455101966858, 6.849733417252121e-33, -0.02169221080839634, 0.08225710690021515, -0.023381687700748444, -0.04909456521272659, 0.02516227960586548, 0.04394843429327011, -0.029969576746225357, -0.015497158281505108, 0.012435509823262691, -0.12105175852775574, -0.1818903684616089, 0.06411720812320709, -0.03505641222000122, -0.05906563252210617, 0.06856197118759155, -0.1154046356678009, 0.006682606413960457, 0.08220148086547852, -0.013608690351247787, -0.052211396396160126, 0.0167489405721426, -0.002712072804570198, -0.06267254054546356, 0.08103057742118835, -0.03437899798154831, 0.047455258667469025, -0.006073093973100185, 0.08850805461406708, -0.17587915062904358, -0.01024063490331173, -0.017728904262185097, 0.0841648131608963, 0.06603406369686127, -0.12767226994037628, -0.020135797560214996, -0.0003761462867259979, -0.026369506493210793, -0.018875401467084885, 0.14438307285308838, 0.0953175351023674, -0.07878027856349945, 0.134736105799675, -0.14409780502319336, -0.1304105818271637, -0.012555750086903572, -0.021051835268735886, -0.11397968232631683, 0.052085116505622864, 0.0007687592878937721, -0.016586940735578537, 0.003998130559921265, 0.04058066010475159, 0.016173098236322403, -0.00237200316041708, -0.06346048414707184, 0.08389021456241608, -0.2177451252937317, -0.17638924717903137, 0.029136305674910545, 0.08980588614940643, 0.15893730521202087, 0.23048946261405945, 0.05802897736430168, -0.03691032901406288, -0.25848662853240967, 0.179691880941391, 0.014072723686695099, 0.005578968673944473, -0.08640926331281662, 0.223791241645813, -0.05684187635779381, 0.036949437111616135, 0.061521708965301514, 0.026916736736893654, 0.26741132140159607, -0.017951538786292076, 0.0016190223395824432, 0.018558580428361893, 0.11425821483135223, -0.009574921801686287, 0.022353054955601692, -0.03293364495038986, 0.09141500294208527, 0.07490772008895874, -0.04046689718961716, -0.09179525077342987, 0.03911295533180237, 0.14177656173706055, 0.012439411133527756, -0.024546809494495392, 0.10523301362991333, -0.11774273961782455, -0.08517123758792877, 0.1162932887673378, 0.006410988047719002, -8.850157377386843e-33, -0.01665022224187851, 0.011186134070158005, 0.03624151274561882, -0.06311965733766556, -0.11846071481704712, 0.037005383521318436, 0.03902354836463928, 0.17912352085113525, 0.027077138423919678, -0.08184891939163208, 0.05088472738862038, 0.1315244436264038, -0.1483219861984253, 0.034023161977529526, -0.07356701791286469, 0.07761533558368683, 0.10842636227607727, -0.1415109783411026, 0.04619794338941574, -0.03163044899702072, -0.0158598143607378, 0.16888564825057983, -0.03066706471145153, 0.0724252313375473, 0.04464036971330643, 0.07378533482551575, -0.036583930253982544, 0.12886708974838257, -0.05157029256224632, -0.06265950202941895, 0.00825466588139534, -0.053836189210414886, -0.15929394960403442, -0.016177980229258537, -0.05348826199769974, -0.03162824735045433, -0.07595287263393402, -0.1347932666540146, -0.07882966101169586, -0.01128885243088007, 0.18620704114437103, -0.04892611876130104, 0.07020958513021469, 0.037582073360681534, 0.12266284227371216, 0.0025779418647289276, 0.09726737439632416, -0.05704169347882271, 0.17810672521591187, -0.024174673482775688, 0.010912610217928886, 0.004898834973573685, -0.04047703370451927, 0.14302146434783936, -0.020044004544615746, 0.03701850399374962, -0.09361466765403748, -0.10759852081537247, -0.13837802410125732, -0.04936289042234421, 0.031972091645002365, 0.1277940571308136, -0.009643659926950932, 0.04618682339787483, 0.027205947786569595, 0.014286880381405354, -0.013115509413182735, -0.095192089676857, 0.002587917260825634, -0.044809721410274506, 0.09391899406909943, -0.004997864365577698, 0.030469488352537155, -0.1388702094554901, 0.03895200043916702, 0.28230202198028564, -0.04530996456742287, -0.19976867735385895, -0.19157937169075012, -0.025672225281596184, -0.007248895242810249, 0.04695358872413635, 0.008679188787937164, 0.004044016823172569, -0.18898916244506836, 0.1717633455991745, 0.04789645969867706, -0.0593792088329792, -0.054916851222515106, -0.00035383179783821106, -0.07928047329187393, -0.1523023396730423, -0.09458866715431213, 0.0013655428774654865, 0.09224680066108704, -1.0016769635967648e-07, 0.042452819645404816, 0.08571121841669083, 0.004729259759187698, -0.034853510558605194, 0.10340752452611923, 0.011186747811734676, -0.04312371462583542, -0.035601720213890076, 0.08675648272037506, 0.06625005602836609, -0.010883146896958351, 0.08846739679574966, -0.11727312207221985, 0.02768716588616371, -0.16091524064540863, 0.038046400994062424, -0.0842105820775032, 0.054642532020807266, 0.0525214746594429, -0.12030716240406036, -0.18632371723651886, 0.07297170162200928, 0.05773027986288071, -0.10175444185733795, 0.06082644313573837, -0.0016840086318552494, -0.03463996946811676, -0.02682362124323845, -0.003863781690597534, 0.019050786271691322, 0.05711061507463455, -0.006469845771789551, 0.07348977774381638, 0.055916108191013336, 0.00801676046103239, -0.13384854793548584, 0.08044997602701187, 0.027268311008810997, 0.040478214621543884, 0.008050773292779922, 0.029538283124566078, 0.01644863747060299, 0.013520109467208385, 0.046249520033597946, -0.05183710157871246, -0.11813613772392273, -0.05721797049045563, -0.033175498247146606, 0.009714702144265175, -0.26017916202545166, 0.19884781539440155, -0.04705507680773735, 0.01879260502755642, -0.010967405512928963, 0.13427984714508057, -0.02674238383769989, -0.16648226976394653, -0.061748139560222626, -0.25374510884284973, -0.08333489298820496, 0.035997916013002396, -0.21791425347328186, 0.01955704391002655, 0.17367330193519592], "changes": {"1wk": 13.274334229301918, "1mo": 68.58406897597216}}, {"text": "ACRS Stock Up on Licensing Deal With Biosion for Two Immunology Drugs Zacks Equity Research Tue, Nov 19, 2024, 5:19 PM 4 min read In This Article: ACRS -3.23% PFE -1.21% Shares of Aclaris Therapeutics ACRS rallied 53.2% on Monday and gained another 8.9% during the after-market hours following the signing of an exclusive license agreement with\u00a0Biosion for global rights (excluding\u00a0Greater China)\u00a0to two of the latter\u2019s pipeline candidates, BSI-045B and BSI-502. Biosion\u2019s BSI-045B, a novel anti-TSLP monoclonal antibody, is currently in clinical development in the United States for treating moderate-to-severe atopic dermatitis. Results from a completed phase IIa proof-of-concept study by Biosion demonstrated that BSI-045B has a pharmacodynamic, safety and efficacy profile indicative of its potential as a best-in-class therapy. Several mid-stage studies of the candidate are ongoing in China for severe asthma and chronic rhinosinusitis with nasal polyps, aiming to accelerate potential proof-of-concept demonstrations for additional indications. The other investigational candidate, per the terms of the licensing deal, is BSI-502, a potential best-in-class, novel bispecific antibody that is directed against both TSLP and IL4R, which is currently in the preclinical stage. However, both candidates are yet to be evaluated by regulatory authorities. Year to date, shares of Aclaris have skyrocketed 199% against the industry\u2019s 6% decline. Zacks Investment Research Image Source: Zacks Investment Research Per management, the licensing deal with Biosion concludes Aclaris\u2019 strategic review process to maximize shareholders\u2019 value. The addition of these two potentially transformative treatments is expected to complement Aclaris\u2019 existing ITK inhibitor portfolio, resulting in a pipeline of differentiated assets that target multiple high-value immunologic and respiratory indications. Aclaris\u2019 pipeline currently comprises several candidates undergoing clinical development across various stages for skin disease and cancer indications. Cash Consideration for the Deal Between ACRS and Biosion Per the terms of the licensing agreement, Aclaris is liable to make a $30 million upfront payment to Biosion for the transfer of global rights to BSI-045B and BSI-502. Biosion is also entitled to receive $4.5 million for certain development costs and $6.2 million for certain development and drug product reimbursement from Aclaris. Moreover, Aclaris is liable to make additional payments of up to $125 million upon the achievement of specified regulatory milestones and up to $795 million upon the achievement of specified sales milestones. Biosion also remains eligible to receive a tiered low-to-mid single-digit royalty based upon a percentage of annual net sales from Aclaris. Story Continues In a separate press release, ACRS announced a private offering for gross proceeds of approximately\u00a0$80 million, which is expected to close on or about\u00a0Nov. 19, 2024, subject to the satisfaction of customary closing conditions. The company intends to use the proceeds from this transaction to fund the research and development of its pipeline and for general corporate purposes. Management believes that this private placement will strengthen Aclaris\u2019 balance sheet and provide enough flexibility to support its strategic growth while maintaining its cash runway into 2028. Aclaris Therapeutics, Inc. Price and Consensus Aclaris Therapeutics, Inc. Price and Consensus Aclaris Therapeutics, Inc. price-consensus-chart | Aclaris Therapeutics, Inc. Quote ACRS\u2019 Zacks Rank and Stocks to Consider Aclaris currently carries a Zacks Rank #3 (Hold). Some better-ranked pharma stocks are Allogene Therapeutics ALLO, Pfizer PFE and Gilead Sciences GILD, each carrying a Zacks Rank #2 (Buy) at present.\u00a0You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here . Over the past 60 days, Allogene Therapeutics\u2019 estimates for loss per share have narrowed from $1.40 to $1.35 for 2024, and that for 2025 has narrowed from $1.46 to $1.34. ALLO shares have lost 33% year to date. Allogene Therapeutics\u2019 earnings beat estimates in three of the trailing four quarters and matched once, delivering an average surprise of 9.42%. Over the past 60 days, Pfizer\u2019s earnings estimates have risen from $2.62 to $2.88 per share for 2024, while that for 2025 has increased from $2.85 to $2.92. PFE shares have lost 13.6% year to date. Pfizer\u2019s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 74.50%. Over the past 60 days, Gilead Sciences\u2019 earnings estimates have risen from $3.79 to $4.28 per share for 2024 while that for 2025 has increased from $7.24 to $7.40. GILD shares have risen 9.2% year to date. Gilead Sciences\u2019 earnings beat estimates in three of the trailing four quarters and missed the same in one, delivering an average surprise of 15.46%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Pfizer Inc. (PFE) : Free Stock Analysis Report Gilead Sciences, Inc. (GILD) : Free Stock Analysis Report Aclaris Therapeutics, Inc. (ACRS) : Free Stock Analysis Report Allogene Therapeutics, Inc. (ALLO) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "ACRS", "date": "2024-11-19T17:19:00", "sentiment": {"score": 0.8996752724051476, "confidence": 0.9091911911964417, "probabilities": {"positive": 0.9091911911964417, "negative": 0.009515918791294098, "neutral": 0.08129288256168365}}, "embedding": [-0.11229495704174042, -0.05574868246912956, 0.0005492219934239984, -0.09182174503803253, 0.0070470180362463, -0.06497637927532196, 0.002382297068834305, 0.20536500215530396, 0.013216452673077583, 0.0847386047244072, -0.07206416875123978, 0.057993993163108826, 0.024400198832154274, 0.17560437321662903, -0.009417595341801643, 0.17151562869548798, -0.020131900906562805, 0.06151473894715309, -0.12431526929140091, -0.010994689539074898, -0.0027885381132364273, 0.010700837709009647, 0.01963166892528534, 0.03717288374900818, -0.15833362936973572, -0.09782840311527252, -0.15684166550636292, -0.06845564395189285, -0.12338976562023163, -0.059874944388866425, -0.010981915518641472, 0.12453101575374603, 0.001681947149336338, -0.07629984617233276, -0.06703748553991318, -0.04791652783751488, -0.13410842418670654, 0.08232167363166809, 0.03298399597406387, 0.01919165812432766, 0.030046653002500534, -0.018354332074522972, -0.1491115391254425, -0.055030398070812225, 0.021410996094346046, -0.11482304334640503, -0.10145197808742523, 0.08427565544843674, 0.09674738347530365, 0.14454805850982666, -0.11132045090198517, -0.020083334296941757, -0.027141844853758812, 0.01568654365837574, -0.21935005486011505, 0.015135906636714935, -0.11523838341236115, -0.19542264938354492, -0.004759269766509533, 0.03642870858311653, -0.08650386333465576, -0.1400335729122162, 0.03427964076399803, 0.07013122737407684, 0.013741699978709221, 0.08279542624950409, -0.001949808094650507, -0.02649177983403206, 0.001876235008239746, 0.029708225280046463, -0.03492843732237816, -0.08034797012805939, -0.04303080961108208, 0.17094826698303223, 0.044480010867118835, 0.04390932619571686, 0.11176460981369019, 0.0745069831609726, 0.13981956243515015, -0.16200986504554749, 0.013563594780862331, 0.04008305445313454, 0.08009743690490723, -0.017388049513101578, 0.08473534882068634, -0.001229585031978786, -0.01033513993024826, 0.10554112493991852, 0.03142751380801201, 0.02302105724811554, 0.15906935930252075, 0.011149788275361061, 0.009466765448451042, -0.02155197039246559, 0.14377668499946594, -0.058951228857040405, -0.038617704063653946, 0.045805349946022034, 0.035436056554317474, -0.045699186623096466, -0.05162607133388519, -0.1548144519329071, -0.0743212103843689, -0.11995327472686768, 0.04892975836992264, -0.1511298418045044, 0.04729994386434555, -0.1778470277786255, 0.09948201477527618, 0.07893408834934235, -0.07802588492631912, 0.06533978879451752, -0.004390627611428499, -0.09164987504482269, 0.021118685603141785, 0.24130088090896606, -0.10274593532085419, 0.013782227411866188, 0.23805758357048035, -0.08825092762708664, 0.06703349947929382, -0.030586054548621178, -0.08013398945331573, -0.11755101382732391, 0.10606344789266586, 0.005720078945159912, -0.11465466022491455, 6.365669986371288e-33, -0.08527283370494843, 0.1252741813659668, 0.01628759875893593, 0.05429801344871521, -0.02000601775944233, 0.008585727773606777, 0.0574706606566906, 0.027461092919111252, -0.1722104698419571, 0.03188431262969971, -0.22503900527954102, 0.021516386419534683, -0.03727255389094353, 0.10430989414453506, 0.06783709675073624, -0.07904372364282608, 0.024449914693832397, 0.06198640540242195, -0.02827526070177555, -0.11530761420726776, 0.03768536448478699, 0.10386434942483902, -0.04602593928575516, 0.0839371308684349, -0.08604530990123749, 0.04690873995423317, 0.009525196626782417, 0.06680928170681, -0.0024012383073568344, -0.002358155557885766, 0.004204247612506151, 0.1132037490606308, -0.029499217867851257, -0.039746783673763275, 0.05893838405609131, -0.008018683642148972, -0.028005195781588554, -0.04574856907129288, -0.009959911927580833, 0.0936487466096878, 0.0657934844493866, 0.08424878120422363, -0.1764512062072754, -0.05338750407099724, 0.11688002943992615, 0.026119917631149292, -0.20269592106342316, 0.021141065284609795, 0.02731453999876976, -0.03826088830828667, 0.03656225651502609, 0.048339758068323135, -0.017573537304997444, -0.03212035074830055, 0.03440931811928749, 0.027443839237093925, -0.12896262109279633, -0.04213971644639969, 0.022214744240045547, 0.06942465156316757, 0.07020500302314758, 0.0002532914513722062, 0.026315879076719284, 0.11748442053794861, -0.13595731556415558, 0.1683834195137024, 0.04993962123990059, -0.034479185938835144, -0.11340759694576263, 0.030309954658150673, 0.0391278937458992, -0.04021019488573074, 0.12397414445877075, 0.09190382063388824, 0.20443619787693024, -0.07611250132322311, 0.07899188995361328, 0.1903710663318634, -0.04360653832554817, 0.07260450720787048, -0.00011403928510844707, 0.12596553564071655, -0.002902790904045105, 0.17800375819206238, -0.02429116517305374, -0.11395666003227234, 0.028236858546733856, 0.08097897469997406, 0.00113685370888561, -0.08791805803775787, 0.14571820199489594, -0.03526533395051956, -0.150509774684906, 0.14555826783180237, 0.042737528681755066, -9.605387518535207e-33, -0.02986203134059906, -0.06566675007343292, 0.06302379816770554, -0.07575735449790955, -0.1563388556241989, 0.142472505569458, 0.10106198489665985, 0.06410142034292221, 0.12325803935527802, -0.059474408626556396, 0.12046723067760468, 0.03957974165678024, -0.0028340057469904423, -0.01921149715781212, -0.0823148638010025, 0.040217526257038116, -0.06503017246723175, -0.011999518610537052, -0.15742342174053192, 0.15125548839569092, 0.03922153264284134, 0.16393087804317474, 0.019060753285884857, 0.03137001767754555, 0.06927554309368134, 0.06666475534439087, 0.00724800955504179, 0.125629723072052, 0.11197082698345184, -0.05960318446159363, -0.056400101631879807, 0.11670166254043579, -0.21309494972229004, -0.027346812188625336, -0.0779459998011589, -0.15698856115341187, -0.04412345215678215, -0.14942145347595215, -0.13854852318763733, -0.06092892587184906, -0.04576805233955383, -0.0467391312122345, 0.07291210442781448, 0.030765926465392113, 0.14464512467384338, -0.031623296439647675, 0.08552125841379166, -0.12334077060222626, 0.02685057744383812, -0.09259644150733948, -0.03756605461239815, -0.011786586605012417, 0.12157890200614929, -0.007506842724978924, -0.043141819536685944, -0.03260941058397293, 0.04359211027622223, -0.114193856716156, -0.012615516781806946, -0.07221812009811401, 0.08809943497180939, 0.014392870478332043, 0.06513950228691101, -0.015001551248133183, -0.029556497931480408, 0.11829963326454163, 0.10656780004501343, -0.07373344898223877, 0.07329535484313965, -0.11879119277000427, -0.12038691341876984, -0.05054101347923279, -0.039017729461193085, -0.0854850634932518, 0.019598843529820442, 0.21576201915740967, -0.014761921018362045, -0.12290181964635849, -0.1787097156047821, -0.013834107667207718, -0.15881671011447906, -0.046873629093170166, -0.0006938548758625984, -0.017418410629034042, 0.010499531403183937, -0.046572811901569366, -0.0023972615599632263, -0.08432508260011673, 0.05150466039776802, 0.021988246589899063, -0.09540022164583206, -0.031026089563965797, -0.04562092944979668, 0.09089630097150803, -0.006958036683499813, -1.0105098624535458e-07, 0.11083735525608063, 0.008696116507053375, 0.05630927160382271, -0.11270581930875778, -0.07352733612060547, 0.07849100232124329, -0.1187167763710022, -0.039043426513671875, -0.006619561929255724, 0.09014391899108887, -0.10244332998991013, 0.18015874922275543, -0.07024107128381729, 0.011359382420778275, -0.12976114451885223, -0.03321482986211777, -0.09732931852340698, -0.0004731547087430954, 0.04336036741733551, -0.024583224207162857, -0.11634467542171478, 0.03794040530920029, 0.07215570658445358, -0.08831334114074707, 0.06835980713367462, -0.02401735447347164, 0.02782203070819378, 0.04802897945046425, 0.05160226300358772, -0.08163951337337494, -0.06831929832696915, -0.005947805941104889, 0.04875021427869797, -0.0024366152938455343, 0.04269421845674515, -0.04985396936535835, 0.049334339797496796, -0.025501923635601997, 0.10413457453250885, 0.062214359641075134, 0.07623104751110077, -0.04834248870611191, -0.0017437925562262535, 0.02898976020514965, 0.03375411033630371, -0.1388925015926361, -0.06777925044298172, -0.10268379747867584, 0.12796027958393097, -0.12493667751550674, 0.04740912839770317, -0.027647268027067184, -0.042897291481494904, -0.10556940734386444, -0.07420457899570465, 0.14319434762001038, -0.12540677189826965, -0.09578181058168411, -0.03609864413738251, 0.02688044309616089, 0.005625901743769646, -0.265053927898407, 0.03663419187068939, 0.03595510870218277], "changes": {"1wk": -13.071898106863047, "1mo": -32.89760737873792}}, {"text": "Pony AI, Thermo Fisher initiated: Wall Street's top analyst calls The Fly Mon, Dec 23, 2024, 5:35 PM 3 min read In This Article: TMO -0.67% Pony AI, Thermo Fisher initiated: Wall Street's top analyst calls The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top Upgrades: H.C. Wainwright upgraded Aclaris Therapeutics (ACRS) to Buy from Neutral with a $20 price target after the company entered into an exclusive license agreement with privately held Biosion. Raymond James upgraded Weyerhaeuser (WY) to Outperform from Market Perform with a $32 price target, citing improving lumber fundamentals and \"deep valuation discount.\" Raymond James upgraded PotlatchDeltic (PCH) to Outperform from Market Perform with a $45 price target. The firm sees a steadily improving backdrop forming for lumber price fundamentals. Piper Sandler upgraded GCM Grosvenor (GCMG) to Overweight from Neutral with a price target of $14, up from $12.50. There has been a \"noticeable shift in sentiment\" in the alternatives space in recent months and Piper does not believe the discounted valuation that GCM Grosvenor is trading at is warranted. Top Downgrades: William Blair downgraded Applied Therapeutics (APLT) to Market Perform from Outperform without a price target. While the management turnover \"was a necessary step in beginning to rebuild the company s reputation and credibility,\" Applied's business update makes it increasingly unclear when it could begin generating revenue given the marketing authorization application in galactosemia was withdrawn and the new drug application in sorbitol dehydrogenase will no longer be submitted in Q1, the firm tells investors in a research note. Jefferies downgraded Mesoblast (MESO) to Hold from Buy with a price target of A$2.30, up from A$1.10. After Mesoblast's recent share price appreciation, the firm downgraded the shares on valuation. BTIG downgraded Innovative Industrial Properties (IIPR) to Neutral from Buy with no price target. The firm cites the company's announcement last week that its largest tenant, multistate operator PharmaCann which accounts for 16.5% of the company's annualized base rent, had failed to pay December rent at its six cultivation facilities. Alliance Global Partners also downgraded Innovative Industrial Properties to Neutral from Buy with a price target of $75, down from $130, following the announcement of PharmaCann defaulting on its rent payment in December. Top Initiations: BofA initiated coverage of Pony AI (PONY) with a Buy rating and $18 price target. BofA likes Pony's proprietary Virtual Driver technology, and believes the Chinese government will continue to have policies for the robotaxi/robotruck industry and to support industry leaders like Pony, against the backdrop of mobility transformation becoming a key area of technology competition between China and the U.S. Scotiabank initiated coverage of Thermo Fisher Scientific (TMO) , Danaher (DHR) , Waters Corporation (WAT) , all with Sector Perform ratings, and price targets of $605, $265 and $430, respectively. The firm's long-term outlook for the life science tools sector \"has been and remains bullish,\" but in the near term, Scotiabank is more neutral on these large cap names given continued end-market uncertainties, particularly with biopharma and China, and, to a lesser extent, any political uncertainties exiting 2024. Brookline initiated coverage of Exelixis (EXEL) with a Buy rating. The firm anticipates Exelixis will continue to develop its commercial drugs, Cabometyx, and Cometriq, while its partner Genentech will continue to develop Cotellic. H.C. Wainwright initiated coverage of enGene (ENGN) with a Buy rating and $25 price target. The firm says the non-muscle invasive bladder cancer treatment landscape is undergoing a renaissance, and enGene's detalimogene \"represents an innovative treatment option.\" H.C. Wainwright initiated coverage of Sanara MedTech (SMTI) with a Buy rating and $50 price target. The medical technology company is focused on the development and commercialization of products and services that improve clinical outcome in the surgical and chronic wound care markets and the company's successful strategy of market penetration and geographic expansion could continue to drive topline growth in the coming quarters, the firm tells investors. View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "ACRS", "date": "2024-12-23T17:35:43", "sentiment": {"score": 0.8632070645689964, "confidence": 0.9000217914581299, "probabilities": {"positive": 0.9000217914581299, "negative": 0.03681472688913345, "neutral": 0.06316345930099487}}, "embedding": [-0.10095840692520142, -0.12053844332695007, -0.06165352836251259, 0.00765670370310545, -0.009369703941047192, -0.005610848776996136, 0.0005973563529551029, 0.2009526938199997, 0.07194085419178009, 0.0530027337372303, 0.012290209531784058, 0.06004573777318001, -0.058906618505716324, 0.002140684984624386, -0.04221836104989052, -0.003895615227520466, 0.18771305680274963, -0.021524857729673386, -0.17016440629959106, 0.07724739611148834, -0.0746643915772438, -0.038755275309085846, -0.10480703413486481, 0.01638897694647312, 0.03554657846689224, -0.0373225212097168, -0.07215414941310883, 0.011818841099739075, -0.09135716408491135, -0.07353821396827698, -0.038693539798259735, 0.1022055447101593, 0.09612080454826355, -0.06894104182720184, -0.025526851415634155, -0.0393945574760437, -0.05953790247440338, 0.09199421107769012, 0.09468924254179001, -0.009669791907072067, 0.004666230641305447, -0.06037576124072075, -0.13881590962409973, 0.04599207639694214, 0.002278772182762623, -0.1034710630774498, 0.05225575715303421, -0.001580529846251011, 0.01359456405043602, 0.05688165873289108, -0.11564748734235764, -0.01133202388882637, 0.007208491675555706, 0.029576117172837257, -0.06625428795814514, 0.052165158092975616, 0.0015913713723421097, 0.06021944433450699, 0.04440464824438095, -0.10092879086732864, -0.06132452189922333, -0.03904328495264053, -0.012968377210199833, 0.0841597467660904, 0.07039026916027069, -0.051999397575855255, -0.04162256419658661, -0.03333317115902901, -0.013796655461192131, -0.0018540360033512115, 0.1407332420349121, -0.035662345588207245, -0.02661311626434326, -0.1165986955165863, 0.048454008996486664, 0.16616469621658325, 0.1122795045375824, 0.004160989075899124, 0.1600150316953659, -0.10374142229557037, 0.06507140398025513, -0.09710904210805893, -0.03289320319890976, -0.0721842423081398, -0.02591082826256752, -0.05813640356063843, 0.039300575852394104, 0.043198589235544205, 0.08598645776510239, -0.019110923632979393, 0.14171092212200165, -0.05997783690690994, -0.12005849182605743, 0.024647876620292664, 0.007572799921035767, 0.0017865849658846855, -0.08499014377593994, 0.011482302099466324, -0.0014966297894716263, 0.0606205090880394, 0.055847860872745514, 0.0775085911154747, -0.06775116175413132, -0.052375756204128265, -0.06325283646583557, -0.08460463583469391, 0.042837776243686676, 0.029425840824842453, 0.11179456114768982, -0.004326516762375832, -0.11725960671901703, -0.013226129114627838, 0.02661396935582161, -0.07215782254934311, -0.07023446261882782, 0.057057250291109085, -0.024453865364193916, 0.014005759730935097, 0.005189800634980202, -0.005517004057765007, 0.06003209203481674, 0.05226850509643555, -0.03497826308012009, 0.009023956954479218, -0.05070213973522186, 0.03999073803424835, -0.07350064069032669, 1.2349584958001592e-32, -0.04614511877298355, -0.037591077387332916, -0.016609981656074524, -0.08758506178855896, 0.04454093426465988, -0.037071846425533295, -0.017041414976119995, -0.0022824008483439684, -0.06384757161140442, -0.0056213922798633575, -0.021429147571325302, 0.040526606142520905, -0.01654757186770439, -0.0322437584400177, 0.017762407660484314, -0.05920559912919998, -0.059877797961235046, 0.008110829629004002, 0.03193282335996628, 0.019348500296473503, 0.038754940032958984, 0.08248589932918549, -0.12138912081718445, -0.006791936699301004, -0.05909547582268715, 0.08453910797834396, 0.07559990882873535, 0.027586553245782852, -0.044324859976768494, 0.07249210774898529, -0.050344593822956085, 0.007776856422424316, -0.03044632449746132, -0.004820670932531357, -0.054347924888134, -0.052637454122304916, -0.10387254506349564, -0.13002672791481018, 0.06528592854738235, -0.029333040118217468, -0.09897130727767944, 0.10568773746490479, -0.03417487069964409, -0.018772194162011147, 0.037041075527668, -0.0658133327960968, -0.0519348569214344, 0.0561138391494751, -0.029059451073408127, 0.03956025838851929, -0.023660503327846527, 0.019464775919914246, 0.02972078137099743, 0.02676011063158512, -0.11569733917713165, 0.0054968781769275665, -0.062411174178123474, -0.027576223015785217, 0.05911920964717865, 0.06177579611539841, 0.05341169238090515, 0.1966754049062729, -0.06584544479846954, -0.0030953288078308105, -0.12155935168266296, 0.07854636758565903, -0.04550714045763016, -0.014124792069196701, -0.08237506449222565, 0.15965816378593445, -0.005505180452018976, -0.009922677651047707, 0.048312969505786896, -0.0106742512434721, 0.03529733046889305, -0.07282945513725281, 0.015248122625052929, 0.10363712906837463, 0.07069741934537888, -0.08064503967761993, -0.0537523552775383, 0.024672821164131165, -0.002097862306982279, 0.01359799224883318, -0.060733940452337265, -0.13352465629577637, -0.044619619846343994, 0.013957994058728218, -0.04998161643743515, 0.02494356967508793, 0.018183857202529907, -0.02202918939292431, -0.12404393404722214, 0.16019845008850098, 0.050257470458745956, -1.1808493888058554e-32, -0.10835793614387512, 0.04163539782166481, -0.06750065088272095, 0.0664040744304657, -0.06391960382461548, 0.045204415917396545, -0.0016020489856600761, -0.09687820076942444, 0.07098536193370819, -0.09320591390132904, -0.028861429542303085, 0.12237109243869781, -0.04547794535756111, 0.038377560675144196, -0.035586822777986526, 0.02869759500026703, -0.006812965963035822, -0.071983203291893, -0.029592962935566902, -0.07671332359313965, 0.07714797556400299, 0.19186624884605408, -0.16159692406654358, 0.10495279729366302, -0.0042086318135261536, 0.084671750664711, 0.0325651615858078, 0.12593117356300354, 0.029250789433717728, -0.007530786097049713, -0.04351678490638733, -0.0028680115938186646, -0.13343283534049988, 0.06985199451446533, -0.053028203547000885, 0.1017066240310669, 0.07827144116163254, -0.09655751287937164, -0.088657908141613, 0.047018177807331085, 0.12242188304662704, -0.012725891545414925, 0.07672987878322601, 0.026605049148201942, 0.05385152995586395, -0.042699795216321945, 0.0005038888193666935, -0.1129605621099472, 0.1709907054901123, 0.01854904741048813, -0.010677510872483253, 0.07109984755516052, 0.000398772768676281, 0.18921467661857605, -0.07009852677583694, 0.03364806994795799, 0.10444168001413345, -0.0006087410729378462, -0.1048751026391983, -0.018858155235648155, 0.017393773421645164, 0.15587137639522552, 0.05730406194925308, -0.04056446626782417, 0.02049248293042183, 0.1111067533493042, 0.06417044997215271, -0.1136508360505104, 0.011871532537043095, -0.10420514643192291, 0.007393630221486092, -0.00946728978306055, 0.0762566328048706, -0.07961969822645187, 0.04091373085975647, 0.07764854282140732, -0.003099581226706505, -0.07786049693822861, -0.06813738495111465, -0.12201531231403351, -0.05412641912698746, -0.017397603020071983, 0.0575292594730854, 0.028064589947462082, 0.0155593641102314, -0.01811906136572361, -0.00012200698256492615, 0.05937599390745163, -0.045259904116392136, -0.005393030121922493, -0.025304682552814484, -0.11959744989871979, -0.05100619047880173, -0.00043139606714248657, -0.03298964351415634, -1.0072987777220987e-07, -0.06959512829780579, 0.029930654913187027, 0.003043713979423046, 0.054619982838630676, 0.11952909827232361, -0.04398750513792038, -0.02226732298731804, 0.0757228434085846, 0.02611491084098816, 0.1338454931974411, 0.1373606026172638, 0.08074292540550232, -0.07130196690559387, 0.027462348341941833, 0.017627794295549393, 0.038821011781692505, -0.09339667856693268, -0.05965324118733406, -0.0459771454334259, -0.04669728875160217, -0.062395788729190826, 0.05222053453326225, -0.04637410491704941, -0.05739264562726021, 0.05698350816965103, -0.0415000319480896, -0.008972760289907455, 0.03655863553285599, 0.0046465592458844185, 0.06684684008359909, 0.0018061008304357529, 0.04924705997109413, -0.008516194298863411, -0.022221406921744347, 0.07136046141386032, -0.015153083950281143, -0.01933879964053631, 0.09457217901945114, 0.0237574465572834, 0.09109461307525635, -0.060435809195041656, 0.009168129414319992, -0.06937923282384872, 0.035440780222415924, 0.07592952251434326, -0.08727412670850754, -0.17627665400505066, -0.027134813368320465, 0.014429288916289806, -0.1078016608953476, 0.06633996963500977, 0.02817852422595024, 0.013861935585737228, 0.06275373697280884, -0.018303027376532555, -0.007291544694453478, -0.06820957362651825, -0.05701056122779846, -0.107163205742836, 0.004679655656218529, 0.07707957923412323, -0.21744796633720398, 0.021727170795202255, 0.07391897588968277], "changes": {"1wk": -14.18685366602376, "1mo": -10.034608641691454}}, {"text": "News Flash: Analysts Just Made A Meaningful Upgrade To Their Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Forecasts editorial-team@simplywallst.com (Simply Wall St) Tue, Nov 12, 2024, 2:14 PM 3 min read In This Article: ACRS -3.23% Aclaris Therapeutics, Inc. ( NASDAQ:ACRS ) shareholders will have a reason to smile today, with the analysts making substantial upgrades to next year's forecasts. The revenue forecast for next year has experienced a facelift, with analysts now much more optimistic on its sales pipeline. The market may be pricing in some blue sky too, with the share price gaining 21% to US$2.63 in the last 7 days. It will be interesting to see if today's upgrade is enough to propel the stock even higher. After the upgrade, the consensus from Aclaris Therapeutics' eight analysts is for revenues of US$11m in 2025, which would reflect a sizeable 59% decline in sales compared to the last year of performance. Losses are expected to increase slightly, to US$0.56 per share. Yet prior to the latest estimates, the analysts had been forecasting revenues of US$9.7m and losses of US$0.60 per share in 2025. We can see there's definitely been a change in sentiment in this update, with the analysts administering a sizeable upgrade to next year's revenue estimates, while at the same time reducing their loss estimates. Check out our latest analysis for Aclaris Therapeutics NasdaqGS:ACRS Earnings and Revenue Growth November 12th 2024 The consensus price target rose 48% to US$2.30, with the analysts encouraged by the higher revenue and lower forecast losses for next year. Looking at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up against both past performance and industry growth estimates. These estimates imply that sales are expected to slow, with a forecast annualised revenue decline of 51% by the end of 2025. This indicates a significant reduction from annual growth of 42% over the last five years. Compare this with our data, which suggests that other companies in the same industry are, in aggregate, expected to see their revenue grow 10% per year. It's pretty clear that Aclaris Therapeutics' revenues are expected to perform substantially worse than the wider industry. The Bottom Line The most important thing here is that analysts reduced their loss per share estimates for next year, reflecting increased optimism around Aclaris Therapeutics' prospects. Fortunately, they also upgraded their revenue estimates, and are forecasting revenues to grow slower than the wider market. There was also an increase in the price target, suggesting that there is more optimism baked into the forecasts than there was previously. Seeing the dramatic upgrade to next year's forecasts, it might be time to take another look at Aclaris Therapeutics. Story Continues Even so, the longer term trajectory of the business is much more important for the value creation of shareholders. We have estimates - from multiple Aclaris Therapeutics analysts - going out to 2026, and you can see them free on our platform here. Of course, seeing company management invest large sums of money in a stock can be just as useful as knowing whether analysts are upgrading their estimates. So you may also wish to search this free list of stocks with high insider ownership . Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "ACRS", "date": "2024-11-12T14:14:46", "sentiment": {"score": -0.7420824617147446, "confidence": 0.8559128046035767, "probabilities": {"positive": 0.11383034288883209, "negative": 0.8559128046035767, "neutral": 0.030256764963269234}}, "embedding": [-0.13194920122623444, -0.07917709648609161, 0.00808144174516201, 0.08213222771883011, -0.018185485154390335, -0.03864569962024689, -0.058785341680049896, 0.12829148769378662, 0.14855967462062836, 0.06945644319057465, -0.16360770165920258, 0.1864800751209259, 0.017718259245157242, -0.025285564363002777, -0.11905279010534286, 0.015279440209269524, -0.046129949390888214, -0.07343465834856033, -0.1787891983985901, -0.011615799739956856, -0.12986302375793457, -0.03167475759983063, -0.061722561717033386, 0.00237305648624897, 0.08968286216259003, -0.045797478407621384, -0.15912041068077087, -0.059923335909843445, -0.13053765892982483, -0.06280282884836197, -0.0437152236700058, 0.051191821694374084, 0.06611697375774384, -0.05277208983898163, -0.09593367576599121, -0.08110275119543076, -0.017765186727046967, 0.08742263168096542, 0.1447225660085678, 0.05432766303420067, 0.08629421889781952, 0.013666513375937939, -0.11774148046970367, 0.0898655503988266, -0.09343306720256805, -0.14922863245010376, -0.0545736625790596, 0.03491149842739105, -0.004395626485347748, 0.16146492958068848, -0.2397233247756958, -0.010170334950089455, 0.03575938194990158, -0.044589824974536896, -0.09984808415174484, 0.05945385619997978, -0.10455930233001709, -0.09281255304813385, 0.030625056475400925, 0.02484983764588833, -0.06518737226724625, -0.033432282507419586, 0.08333949744701385, 0.06032855063676834, 0.10131385922431946, -0.018209513276815414, 0.07850725948810577, 0.07310816645622253, -0.1451149731874466, 0.06042897701263428, 0.035789698362350464, -0.05292895436286926, -0.003923475742340088, -0.0593697763979435, 0.0408320352435112, 0.08576444536447525, 0.08318421989679337, 0.045331910252571106, 0.08310329169034958, -0.08098720014095306, 0.07906074821949005, -0.042157918214797974, -0.12971314787864685, -0.12930479645729065, -0.06783470511436462, -0.02947806380689144, 0.1679970920085907, -0.04419267177581787, 0.027052082121372223, 0.013287391513586044, 0.08464711904525757, -0.08049824088811874, -0.03287062048912048, 0.03153342008590698, 0.05325685068964958, 0.11102564632892609, -0.10431680083274841, -0.1271277219057083, -0.00022126175463199615, 0.06773017346858978, 0.09989801049232483, 0.17471203207969666, 0.03196755051612854, -0.16825279593467712, -0.08722056448459625, -0.20698390901088715, 0.021349897608160973, 0.0008906843140721321, -0.033877693116664886, 0.09561178088188171, -0.05325595289468765, 0.10913439095020294, -0.15133780241012573, -0.07605642080307007, -0.014077289961278439, 0.0874556377530098, -0.044251393526792526, 0.02409890852868557, 0.06751763075590134, 0.042553722858428955, 0.033551037311553955, 0.11209307610988617, 0.007941676303744316, 0.05882728099822998, 0.09557616710662842, 0.019964704290032387, -0.2377084195613861, 1.086783245180385e-32, -0.09695489704608917, -0.007629061117768288, 0.004889378789812326, -0.1284821480512619, -0.059975266456604004, 0.03440694883465767, -0.02918069437146187, 0.007824582047760487, 0.014008041471242905, -0.0743597000837326, -0.1671697348356247, 0.1316206157207489, -0.005815945565700531, 0.005181768909096718, 0.11304758489131927, -0.13179990649223328, 0.06268122047185898, 0.10844521224498749, -0.0561860054731369, -0.06530216336250305, 0.025908464565873146, 0.11787212640047073, -0.033420007675886154, 0.07520540803670883, -0.004976579919457436, -0.005533795338124037, 0.005782168358564377, 0.0754600316286087, -0.08463683724403381, -0.010594076476991177, -0.05416402965784073, 0.1035347431898117, 0.034442320466041565, -0.08478932082653046, -0.0035316951107233763, -0.05510914698243141, -0.048620741814374924, 0.0035403533838689327, 0.11518038809299469, 0.05659101903438568, -0.04812449961900711, 0.0793527215719223, -0.0776938796043396, -0.107000932097435, 0.02782473713159561, -0.0017108609899878502, -0.0938146710395813, -0.008763626217842102, -0.0744459331035614, -0.08945542573928833, -0.013990610837936401, 0.029387542977929115, -0.039358481764793396, -0.00585518404841423, 0.023210788145661354, 0.05016574636101723, -0.1205296441912651, -0.18468575179576874, 0.13774870336055756, 0.011694859713315964, 0.041666917502880096, 0.11962131410837173, 0.053245119750499725, -0.0702589675784111, -0.28615590929985046, 0.17469054460525513, 0.06575055420398712, 0.042012058198451996, -0.05505877360701561, 0.13946275413036346, 0.04546412080526352, -0.0001350898528471589, 0.0036474689841270447, 0.029873713850975037, 0.22736655175685883, -0.0030253371223807335, -0.009886704385280609, 0.039732396602630615, 0.08615246415138245, 0.0406368188560009, 0.02035713568329811, 0.05233019217848778, 0.11680375039577484, 0.0326150581240654, 0.07669934630393982, -0.11952007561922073, 0.03941506892442703, 0.14679847657680511, 0.0031940052285790443, -0.03243575245141983, 0.09232582151889801, -0.022925211116671562, -0.10657081007957458, 0.17982465028762817, 0.03678241744637489, -1.2691739037431312e-32, 0.004663087427616119, 0.000845673494040966, 0.0075196512043476105, -0.0542781800031662, -0.12629839777946472, -0.05878570303320885, 0.0573333203792572, 0.09825381636619568, -0.017725467681884766, -0.11376123130321503, 0.03152644261717796, 0.12047329545021057, -0.06797156482934952, 0.03527515381574631, -0.056437935680150986, -0.015013175085186958, 0.2060496211051941, -0.09135591983795166, -0.0035749063827097416, -0.07778339087963104, -0.038586728274822235, 0.2157284915447235, -0.08887786418199539, 0.09079203009605408, -0.005250649526715279, 0.009935245849192142, 0.04054822027683258, 0.15790286660194397, 0.0012865550816059113, -0.07916030287742615, -0.1092986986041069, -0.05545833706855774, -0.15551891922950745, 0.053878359496593475, -0.02322535589337349, 0.008018087595701218, -0.007011828012764454, -0.18768185377120972, -0.10004889965057373, -0.03221309930086136, 0.12863077223300934, -0.013707454316318035, 0.03225993365049362, -0.005103426054120064, 0.14879277348518372, 0.038624219596385956, 0.10082337260246277, -0.016726959496736526, 0.13904345035552979, 0.04452422633767128, 0.09100587666034698, 0.027235135436058044, -0.012893324717879295, 0.05364910513162613, -0.058149971067905426, 0.02162250503897667, -0.017947304993867874, -0.09604869782924652, -0.08272641152143478, 0.02273288369178772, 0.032052330672740936, 0.08959245681762695, 0.04445169121026993, -0.051917314529418945, -0.06096154451370239, 0.0197987649589777, 0.016538545489311218, -0.09894628822803497, 0.05200893431901932, -0.046106964349746704, 0.09954403340816498, -0.05448799580335617, -0.10980438441038132, -0.08527524024248123, -0.005792547948658466, 0.21146658062934875, -0.01263949740678072, -0.08130145817995071, -0.06188589334487915, -0.002348157577216625, -0.09693603962659836, 0.039761513471603394, 0.05811864137649536, 0.05070904642343521, -0.1099131628870964, 0.05619651824235916, 0.09152721613645554, -0.07417106628417969, -0.07178881764411926, 0.045735277235507965, -0.10908696055412292, -0.17958617210388184, -0.13143983483314514, 0.01579335518181324, 0.07447872310876846, -1.0080046308758028e-07, -0.01912773586809635, 0.059655431658029556, 0.03595738112926483, 0.024922091513872147, 0.12035209685564041, -0.07240905612707138, -0.02436729706823826, 0.03729061037302017, 0.10746906697750092, 0.1122698187828064, 0.1058899313211441, 0.05979051813483238, -0.09325320273637772, 0.07679808139801025, -0.090030737221241, 0.1161269098520279, -0.12763044238090515, -0.01160532608628273, 0.036804117262363434, -0.17101973295211792, -0.11027853935956955, 0.09649058431386948, 0.09214892238378525, -0.0215916708111763, 0.07531151175498962, -0.06922981888055801, -0.025220554322004318, 0.027276359498500824, -0.056356824934482574, -0.008681230247020721, 0.006866397336125374, -0.03687642142176628, 0.033074915409088135, -0.030387988314032555, 0.018955623731017113, -0.11188042163848877, 0.13315939903259277, 0.04328148812055588, 0.07072547823190689, 0.0302305668592453, -0.027432756498456, -0.045965395867824554, 0.049372348934412, 0.008114553987979889, -0.050178833305835724, -0.15943865478038788, -0.05673599988222122, -0.006528670899569988, 0.04589139670133591, -0.20391401648521423, 0.21086588501930237, -0.048642657697200775, -0.017221447080373764, 0.0179694015532732, 0.1982620507478714, -0.07164308428764343, -0.1591707468032837, -0.09377025812864304, -0.17799003422260284, 0.06000867486000061, 0.001324974000453949, -0.21373435854911804, 0.005494967103004456, 0.14810721576213837], "changes": {"1wk": 22.65625683940031, "1mo": 38.28125160071071}}, {"text": "Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates editorial-team@simplywallst.com (Simply Wall St) Sat, Nov 9, 2024, 5:18 PM 3 min read In This Article: ACRS -3.23% The analysts might have been a bit too bullish on Aclaris Therapeutics, Inc. ( NASDAQ:ACRS ), given that the company fell short of expectations when it released its third-quarter results last week. It was not a great statutory result, with revenues coming in 63% lower than the analysts predicted. Unsurprisingly, earnings also fell seriously short of forecasts, turning into a per-share loss of US$0.11. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. We thought readers would find it interesting to see the analysts latest (statutory) post-earnings forecasts for next year. See our latest analysis for Aclaris Therapeutics NasdaqGS:ACRS Earnings and Revenue Growth November 9th 2024 Taking into account the latest results, the eight analysts covering Aclaris Therapeutics provided consensus estimates of US$11.2m revenue in 2025, which would reflect a concerning 59% decline over the past 12 months. Per-share losses are predicted to creep up to US$0.56. Yet prior to the latest earnings, the analysts had been forecasting revenues of US$9.75m and losses of US$0.60 per share in 2025. So there's been quite a change-up of views after the recent consensus updates, with the analysts making a sizeable increase to their revenue forecasts while also reducing the estimated loss as the business grows towards breakeven. The consensus price target rose 48% to US$2.30, with the analysts encouraged by the higher revenue and lower forecast losses for next year. The consensus price target is just an average of individual analyst targets, so - it could be handy to see how wide the range of underlying estimates is. The most optimistic Aclaris Therapeutics analyst has a price target of US$3.00 per share, while the most pessimistic values it at US$1.20. This is a fairly broad spread of estimates, suggesting that analysts are forecasting a wide range of possible outcomes for the business. One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. We would highlight that revenue is expected to reverse, with a forecast 51% annualised decline to the end of 2025. That is a notable change from historical growth of 42% over the last five years. Compare this with our data, which suggests that other companies in the same industry are, in aggregate, expected to see their revenue grow 10% per year. So although its revenues are forecast to shrink, this cloud does not come with a silver lining - Aclaris Therapeutics is expected to lag the wider industry. Story Continues The Bottom Line The most obvious conclusion is that the analysts made no changes to their forecasts for a loss next year. They also upgraded their revenue estimates for next year, even though it is expected to grow slower than the wider industry. We note an upgrade to the price target, suggesting that the analysts believes the intrinsic value of the business is likely to improve over time. With that in mind, we wouldn't be too quick to come to a conclusion on Aclaris Therapeutics. Long-term earnings power is much more important than next year's profits. At Simply Wall St, we have a full range of analyst estimates for Aclaris Therapeutics going out to 2026, and you can see them free on our platform here. . Even so, be aware that Aclaris Therapeutics is showing 3 warning signs in our investment analysis , and 1 of those is a bit unpleasant... Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "ACRS", "date": "2024-11-09T17:18:56", "sentiment": {"score": -0.7661815658211708, "confidence": 0.8648682236671448, "probabilities": {"positive": 0.09868665784597397, "negative": 0.8648682236671448, "neutral": 0.03644506260752678}}, "embedding": [-0.12668335437774658, -0.05971697345376015, -0.050961993634700775, 0.11341652274131775, -0.013216779567301273, -0.016158515587449074, -0.0424504429101944, 0.17632393538951874, 0.17869791388511658, 0.08144370466470718, -0.1542496681213379, 0.15162689983844757, 0.010634887963533401, 0.00243071629665792, -0.14688125252723694, 0.019532224163413048, 0.004788335878401995, -0.08004125952720642, -0.12648828327655792, 0.02638455480337143, -0.15083734691143036, -0.0026334691792726517, -0.06134842708706856, -0.011867274530231953, 0.12210234254598618, -0.06499938666820526, -0.1109236478805542, -0.07001511007547379, -0.14758415520191193, -0.05834461376070976, -0.05441250652074814, 0.01975245028734207, 0.09351550042629242, -0.05785097926855087, -0.06276427209377289, -0.08040712773799896, -0.05081019923090935, 0.06468173116445541, 0.1187802106142044, 0.047693073749542236, 0.047998324036598206, 0.014673369005322456, -0.11697584390640259, 0.0855770856142044, -0.09342395514249802, -0.17711526155471802, -0.055658549070358276, 0.01073373295366764, -0.022541850805282593, 0.1598660796880722, -0.23187574744224548, -0.05693913996219635, 0.0788627415895462, -0.05479191988706589, -0.1009683907032013, 0.01086182426661253, -0.13469433784484863, -0.10266328603029251, 0.03434184193611145, 0.04096748307347298, -0.05639342963695526, 0.02700323984026909, 0.040833525359630585, 0.09307645261287689, 0.17638759315013885, 0.0063769021071493626, 0.04958708584308624, 0.07612603902816772, -0.12496620416641235, 0.06594447046518326, 0.03863713890314102, -0.07955513894557953, -0.006831799633800983, -0.08715479075908661, 0.03828331455588341, 0.09962673485279083, 0.08713262528181076, 0.053747013211250305, 0.07705086469650269, -0.0724169909954071, 0.045369260013103485, -0.019409650936722755, -0.11787253618240356, -0.12144122272729874, -0.03673475235700607, -0.04239249974489212, 0.14785709977149963, 0.008419563062489033, 0.061419133096933365, 0.014969199895858765, 0.05996845290064812, -0.0371444895863533, -0.03930320963263512, 0.0277194045484066, 0.09581255912780762, 0.08847746253013611, -0.06495732069015503, -0.1369115114212036, 0.002949325367808342, 0.07050132751464844, 0.0763295367360115, 0.12917675077915192, 0.02961752563714981, -0.14788658916950226, -0.0775131955742836, -0.19945967197418213, 0.015578567050397396, -0.021876754239201546, 0.0008084950968623161, 0.10893082618713379, -0.05040614306926727, 0.09950466454029083, -0.12532661855220795, -0.10175321996212006, -0.008220138028264046, 0.059973809868097305, -0.02472037822008133, 0.024514663964509964, 0.08261805772781372, 0.012727550230920315, 0.04096166789531708, 0.10569817572832108, -0.009435340762138367, 0.04114115238189697, 0.09793083369731903, 0.020288011059165, -0.22175610065460205, 9.182743667484839e-33, -0.06027715653181076, 0.0032328832894563675, 0.026811059564352036, -0.11983618140220642, -0.017276041209697723, -0.0020036986097693443, -0.03754327818751335, 0.002119285287335515, 0.026667717844247818, -0.09288818389177322, -0.15244615077972412, 0.11137889325618744, 0.0024640406481921673, 0.0075798192992806435, 0.012223277240991592, -0.11406610906124115, 0.09637512266635895, 0.08724238723516464, -0.04292018711566925, -0.052019380033016205, 0.014966966584324837, 0.08349090069532394, -0.03615415096282959, 0.05091342329978943, -0.009835446253418922, 0.009326125495135784, 0.0034015197306871414, 0.04861089587211609, -0.10688197612762451, 0.008928414434194565, -0.07997926324605942, 0.08101348578929901, -0.004161520395427942, -0.10257638990879059, 0.006922370288521051, -0.029132654890418053, -0.08063933998346329, 0.005095500499010086, 0.12465764582157135, 0.07163948565721512, -0.050358276814222336, 0.08638635277748108, -0.06443236023187637, -0.11574874818325043, 0.04658323898911476, -0.013017384335398674, -0.10754460841417313, -0.0018138331361114979, -0.0928272232413292, -0.11345012485980988, -0.014112492091953754, -0.003027623984962702, -0.05333567410707474, -0.014844032004475594, 0.006690839305520058, 0.060314908623695374, -0.15131931006908417, -0.14295007288455963, 0.12104033678770065, 0.029633691534399986, 0.09315905719995499, 0.1796741485595703, 0.04605557769536972, -0.09097522497177124, -0.2966868281364441, 0.20525595545768738, 0.007103963289409876, 0.061532750725746155, -0.031788088381290436, 0.16496054828166962, 0.00420958548784256, 0.04803721606731415, 0.04534704610705376, 0.02168499119579792, 0.18646837770938873, 0.008054987527430058, -0.006900107022374868, 0.018329184502363205, 0.11367033421993256, 0.05230369418859482, 0.05656634643673897, 0.05938287079334259, 0.08861231803894043, 0.05070366710424423, 0.04347938299179077, -0.10019929707050323, 0.024249881505966187, 0.1499861180782318, -0.03790173679590225, -0.012316267006099224, 0.10787521302700043, -0.03015829063951969, -0.09873789548873901, 0.14447474479675293, 0.0454108789563179, -1.1586973447014032e-32, -0.061748385429382324, -0.007342430297285318, -0.017896177247166634, -0.08234597742557526, -0.09490180015563965, -0.06314848363399506, 0.03619765490293503, 0.11911752074956894, 0.027469664812088013, -0.06473613530397415, 0.05087602138519287, 0.07794315367937088, -0.07929705083370209, 0.02954670414328575, -0.06303795427083969, 0.01233957801014185, 0.14765042066574097, -0.1304270476102829, -0.02463965304195881, -0.025135435163974762, -0.03464719280600548, 0.16052952408790588, -0.08877617120742798, 0.07951074838638306, 0.054346174001693726, 0.01625925488770008, 0.1023034006357193, 0.11563585698604584, -0.032387636601924896, -0.07384917885065079, -0.11475476622581482, -0.04967457056045532, -0.19839903712272644, 0.03535234555602074, -0.025786055251955986, 0.015275329351425171, -0.01659892313182354, -0.15981236100196838, -0.10569117963314056, -0.05620250105857849, 0.14243030548095703, -0.025709060952067375, 0.01167646050453186, 0.0011923667043447495, 0.11319690942764282, 0.01973128505051136, 0.11233237385749817, -0.009400773793458939, 0.13935425877571106, 0.03388097137212753, 0.053495392203330994, -0.00630187476053834, 0.011262386105954647, 0.05840834975242615, -0.04759058728814125, -0.006191259250044823, -0.030139818787574768, -0.1037011444568634, -0.030533377081155777, 0.0119477529078722, -0.016672544181346893, 0.10128515958786011, 0.057829417288303375, -0.039868373423814774, -0.007378324866294861, 0.0007374351844191551, 0.0038377391174435616, -0.06504113972187042, 0.014637120999395847, -0.07004839181900024, 0.11439172923564911, -0.03632768243551254, -0.08863924443721771, -0.09028312563896179, 0.022728243842720985, 0.2301023006439209, -0.025532878935337067, -0.1268051117658615, -0.07484729588031769, 0.025147469714283943, -0.029799524694681168, 0.039072249084711075, 0.08039764314889908, 0.039587780833244324, -0.026533063501119614, 0.07219962030649185, 0.06464970111846924, -0.02461668662726879, -0.06020202860236168, 0.03462502732872963, -0.11996664106845856, -0.19047410786151886, -0.12744194269180298, 0.04550702124834061, 0.055856406688690186, -1.0085855706165603e-07, -0.022820279002189636, 0.06505201756954193, 0.03107362985610962, -0.019214533269405365, 0.11282254010438919, -0.05977975204586983, -0.008275475353002548, -0.030940746888518333, 0.07311242818832397, 0.13139492273330688, 0.07175171375274658, 0.04661349579691887, -0.10356821119785309, 0.061208873987197876, -0.11826679855585098, 0.09712153673171997, -0.08257512748241425, -0.01624823361635208, 0.017721064388751984, -0.16178491711616516, -0.08593781292438507, 0.06777983903884888, 0.06100138649344444, -0.04268176108598709, 0.12988100945949554, -0.08870336413383484, -0.08735933899879456, 0.026189563795924187, -0.06788641959428787, 0.015260173007845879, 0.002794726984575391, -0.011248329654335976, 0.032625555992126465, -0.013447029516100883, 0.012506513856351376, -0.09472653269767761, 0.12864243984222412, 0.05363236367702484, 0.06988248229026794, 0.04520507901906967, -0.03270208090543747, -0.03061097115278244, 0.0694395899772644, 0.014308799058198929, -0.05472591519355774, -0.10683111846446991, -0.04816289246082306, -0.015401131473481655, 0.010131231509149075, -0.20860417187213898, 0.1744818091392517, -0.07961711287498474, 0.02802678570151329, 0.03833471238613129, 0.18473191559314728, -0.06209231913089752, -0.10673342645168304, -0.1019822359085083, -0.19970357418060303, 0.005505315028131008, 0.03843458369374275, -0.21075214445590973, 0.03606147691607475, 0.1649986207485199], "changes": {"1wk": -22.053237143981246, "1mo": 49.809881588465984}}, {"text": "Aclaris Therapeutics upgraded to Buy from Hold at Jefferies TipRanks Wed, Nov 20, 2024, 1:11 PM 1 min read In This Article: ACRS -3.23% https://www.tipranks.com/news/company-announcements/irhythm-technologies-reports-strong-growth-and-innovation Jefferies upgraded Aclaris Therapeutics ( ACRS ) to Buy from Hold with a price target of $7, up from $2. BSI-045B is the first anti-TSLP showing clinical proof of concept in atopic dermatitis, which is likely supported by a differentiated binding profile, the analyst tells investors in a research note. The firm says the data support further development in placebo-controlled study for additional validation in AD and beyond. If successful, BSI-045B could be the first anti-TSLP in the crowded AD space, providing a differentiated mechanism of actin improved efficacy and safety, contends Jefferies. Don't Miss our Black Friday Offers: Unlock your investing potential with TipRanks Premium - Now At 40% OFF! Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter Published first on TheFly \u2013 the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on ACRS: Aclaris Therapeutics upgraded to Buy from Neutral at BTIG Aclaris Therapeutics upgraded to Overweight from Neutral at Piper Sandler Aclaris Therapeutics Expands Pipeline and Strengthens Leadership Aclaris Therapeutics enters global license agreement with Biosion Aclaris Therapeutics to sell 35.5M shares at $2.25 in private placement View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "ACRS", "date": "2024-11-20T13:11:03", "sentiment": {"score": 0.9108695462346077, "confidence": 0.9215599298477173, "probabilities": {"positive": 0.9215599298477173, "negative": 0.010690383613109589, "neutral": 0.06774970889091492}}, "embedding": [-0.23498931527137756, -0.1747553050518036, -0.0678870677947998, 0.0669577494263649, 0.0740537941455841, -0.024321602657437325, 0.11292272806167603, 0.2224700003862381, 0.02531987801194191, 0.10278931260108948, 0.07539734244346619, 0.12125717848539352, -0.04584316909313202, 0.08784991502761841, -0.020971303805708885, 0.10101909935474396, 0.07604336738586426, -0.05091063305735588, -0.16923245787620544, -0.005541951395571232, -0.1306179314851761, -0.041596148163080215, -0.04250670596957207, -0.03173728659749031, -0.07460731267929077, -0.10715923458337784, -0.146077960729599, 0.005366829223930836, -0.09942866116762161, -0.1411551833152771, -0.02432231418788433, 0.0817830041050911, 0.03049072064459324, -0.12613344192504883, -0.056678175926208496, -0.029884856194257736, -0.17610615491867065, 0.02386431023478508, 0.021222935989499092, 0.033726781606674194, 0.042848408222198486, -0.07710100710391998, -0.1878650188446045, 0.06416832655668259, -0.0814710408449173, -0.16016791760921478, -0.024363713338971138, 0.1182175949215889, 0.1424461454153061, 0.16184765100479126, -0.21851560473442078, -0.06876298785209656, 0.04999920725822449, 0.0585397407412529, -0.14172181487083435, 0.022440282627940178, -0.18254540860652924, -0.14338357746601105, -0.037287890911102295, -0.04694926738739014, 0.015876583755016327, -0.1390828788280487, 0.03030392900109291, 0.009275784716010094, 0.027799632400274277, 0.035337287932634354, -0.035604078322649, 0.00034111866261810064, 0.009129906073212624, 0.016926726326346397, 0.06662552058696747, -0.12278646975755692, -0.01433270238339901, 0.0963236466050148, 0.11572281271219254, 0.11917100101709366, 0.057393331080675125, -0.06439768522977829, 0.09943943470716476, -0.025415902957320213, 0.010317583568394184, 0.035967517644166946, 0.0588480569422245, 0.002999099437147379, 0.0071171727031469345, -0.059574782848358154, 0.024694716557860374, 0.10350003838539124, 0.04645909368991852, 0.06594617664813995, 0.1408507078886032, 0.034167543053627014, -0.04921264946460724, -0.0061413804069161415, 0.06639885902404785, 0.017349179834127426, -0.1298683136701584, -0.021844858303666115, -0.04436197504401207, 0.0029975560028105974, -0.042306914925575256, -0.04377590864896774, -0.07218499481678009, -0.013477942906320095, 0.0016376266721636057, -0.21456724405288696, -0.008208212442696095, -0.049759391695261, 0.11466766893863678, -0.015193463303148746, -0.041803259402513504, 0.07791705429553986, 0.01862926408648491, -0.0012241685763001442, -0.11541081219911575, 0.2060232311487198, -0.05865852162241936, -0.012660449370741844, 0.2325032353401184, -0.06825472414493561, 0.12136584520339966, 0.0329606756567955, -0.09742336720228195, -0.08759042620658875, 0.05189702659845352, 0.04321781173348427, -0.18495501577854156, 1.0049624466126212e-32, -0.07908491790294647, 0.1044105589389801, -0.036272093653678894, 0.012051079422235489, -0.004375583492219448, -0.02822142094373703, -0.01891116425395012, 0.021211247891187668, -0.13245545327663422, -0.03332891687750816, -0.1991775631904602, 0.014307300560176373, 0.017114082351326942, 0.11497350037097931, -0.007275838870555162, -0.13178576529026031, 0.054285816848278046, 0.11022824794054031, 0.015776336193084717, -0.07487800717353821, 0.09600377082824707, 0.09395623952150345, -0.0950472503900528, -0.006971545051783323, -0.014648186042904854, 0.11962291598320007, 0.00822898093611002, 0.06394515186548233, 0.10510986298322678, 0.020632082596421242, -0.037274397909641266, 0.10956789553165436, -0.029926566407084465, -0.02184569463133812, 0.032618824392557144, 0.04591422528028488, -0.08818680047988892, -0.12974748015403748, 0.015021756291389465, -0.0063227382488548756, 0.001181347412057221, 0.16159799695014954, -0.11725965887308121, -0.04320525750517845, 0.0819271057844162, -0.08997925370931625, -0.1720755398273468, 0.035264115780591965, 0.008609620854258537, -0.01526310108602047, -0.004163667559623718, 0.05241640284657478, 0.058267414569854736, -0.03197947144508362, -0.0772981345653534, 0.06341249495744705, -0.199761301279068, -0.00514222402125597, 0.036326855421066284, 0.09005236625671387, 0.08644074201583862, 0.04921136796474457, 0.020648419857025146, -0.05090372636914253, -0.21048545837402344, 0.1640709638595581, 0.013892215676605701, -0.10174539685249329, -0.11199774593114853, 0.07988300919532776, 0.054886650294065475, 0.10512781888246536, 0.13832420110702515, 0.06323885172605515, 0.15132440626621246, -0.038951657712459564, 0.015608372166752815, 0.13311892747879028, 0.01618322543799877, -0.0015882350271567702, 0.009735116735100746, 0.019905827939510345, 0.07992023229598999, 0.17315825819969177, -0.03176276758313179, -0.12293735891580582, -0.07216998934745789, 0.09262880682945251, -0.0544702410697937, -0.08620405942201614, 0.11175437271595001, 0.0015363667625933886, -0.18982593715190887, 0.1313331127166748, -0.05477697029709816, -1.09341979241154e-32, -0.018293652683496475, -0.13279639184474945, 0.01121857576072216, -0.056963931769132614, -0.08364421129226685, 0.10612795501947403, -0.007705772295594215, 0.019953470677137375, 0.11214815825223923, -0.06116349622607231, 0.10486076772212982, 0.1764988899230957, -0.09970122575759888, -0.05178026109933853, -0.05906005576252937, 0.03512880951166153, -0.08079401403665543, -0.013287528418004513, -0.037248045206069946, 0.000963482481893152, -0.030190598219633102, 0.18847665190696716, 0.0028686027508229017, 0.2005910575389862, 0.07419997453689575, 0.033090148121118546, 0.004401585087180138, 0.15174828469753265, 0.03142488747835159, 0.037876907736063004, -0.08651559799909592, -0.01180238090455532, -0.23465096950531006, -0.06059512123465538, -0.07777485996484756, 0.014305595308542252, -0.02567305788397789, -0.11031337082386017, -0.06305147707462311, 0.05991324409842491, 0.17867878079414368, -0.06533583998680115, 0.02123207598924637, 0.021047484129667282, 0.12092950940132141, 0.02801504358649254, 0.043723803013563156, -0.07741217315196991, 0.0872069001197815, -0.09432144463062286, 0.023197853937745094, 0.03065040335059166, 0.13353951275348663, -0.006545115727931261, -0.022556450217962265, 0.003973330371081829, 0.10782203823328018, -0.07679367065429688, -0.10003313422203064, -0.025779688730835915, 0.047422077506780624, 0.07326899468898773, 0.049806758761405945, 0.009569637477397919, -0.025501461699604988, 0.0807863399386406, 0.08020831644535065, -0.09862333536148071, 0.04531563073396683, -0.11729550361633301, 0.018679872155189514, -0.06510286778211594, -0.0377223864197731, -0.12245671451091766, -0.014722584746778011, 0.14206956326961517, 0.038394518196582794, -0.13010448217391968, -0.12981900572776794, -0.0211196169257164, -0.10846832394599915, -0.06463700532913208, 0.06062924861907959, 0.07642067968845367, 0.004444481339305639, 0.1316126585006714, 0.019854219630360603, 0.006389646325260401, -0.06139912083745003, 0.051943957805633545, -0.10224787145853043, -0.1162179484963417, -0.10439545661211014, 0.09400881826877594, 0.009209123440086842, -1.0051332566263227e-07, 0.13117966055870056, 0.05636851117014885, 0.10509181022644043, -0.04069817438721657, 0.03594227880239487, 0.048236601054668427, -0.0854720026254654, 0.04822104051709175, 0.025721946731209755, 0.14038504660129547, -0.07305774092674255, 0.15601202845573425, -0.05766403675079346, -0.03548574075102806, -0.061480436474084854, 0.015392415225505829, -0.03575550764799118, 0.0566277876496315, -0.04925154522061348, -0.05012062191963196, -0.11324264854192734, 0.0843314379453659, 0.11585848778486252, -0.012406319379806519, 0.0840647965669632, -0.04058775678277016, 0.07937433570623398, 0.03055506944656372, 0.07738807052373886, -0.028032338246703148, -0.031301349401474, -0.006362368818372488, 0.08873718231916428, 0.027678528800606728, 0.04657251015305519, -0.09399424493312836, 0.009754526428878307, 0.025808073580265045, 0.03535616397857666, 0.09889392554759979, -0.0759316235780716, -0.03168945387005806, -0.010441161692142487, -0.012422677129507065, -0.016903595998883247, -0.07162092626094818, -0.11588595062494278, -0.1482079029083252, 0.11436884105205536, -0.11936336755752563, 0.14658960700035095, -0.028324337676167488, -0.014204004779458046, 0.01974661834537983, -0.03904726356267929, 0.10029179602861404, -0.10278710722923279, -0.05714358016848564, -0.06406071037054062, 0.0005942743155173957, 0.023104365915060043, -0.24517452716827393, -0.030931245535612106, 0.15806077420711517], "changes": {"1wk": -8.333331326442957, "1mo": -30.050506205987386}}, {"text": "Aclaris Therapeutics upgraded to Buy from Neutral at BTIG TipRanks Wed, Nov 20, 2024, 5:30 AM 1 min read In This Article: ACRS -3.23% https://www.tipranks.com/news/the-fly/immunoprecise-antibodies-develops-new-class-of-glp-1-therapies-through-ai BTIG upgraded Aclaris Therapeutics ( ACRS ) to Buy from Neutral with an $8 price target In a \u201ctransformative transaction,\u201d Aclaris has acquired full ex-China rights to an anti-TSLP humanized mAb and anti-TSLP/IL4R bispecific mAb from Chinabased Biosion, the analyst tells investors in a research note. The firm says BSI-045B\u2019s potency is likely best-in-class with 71-times greater potency versus tezepelumab and up to nine-times higher potency versus other anti-TSLP therapies in development. Based on \u201cpromising\u201d Phase 2a open label data, BTIG sees potential for BSI-045B to emerge as a possible early-line treatment option for atopic dermatitis. Don't Miss out on Research Tools: Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter Published first on TheFly \u2013 the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today\u2019s best-performing stocks on TipRanks >> Read More on ACRS: Aclaris Therapeutics upgraded to Overweight from Neutral at Piper Sandler Aclaris Therapeutics Expands Pipeline and Strengthens Leadership Aclaris Therapeutics enters global license agreement with Biosion Aclaris Therapeutics to sell 35.5M shares at $2.25 in private placement Aclaris Therapeutics Reports Positive Q3 2024 Milestones View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "ACRS", "date": "2024-11-20T05:30:12", "sentiment": {"score": 0.8431878620758653, "confidence": 0.8513728976249695, "probabilities": {"positive": 0.8513728976249695, "negative": 0.008185035549104214, "neutral": 0.14044205844402313}}, "embedding": [-0.15782248973846436, -0.12966500222682953, -0.06655754894018173, 0.03267163410782814, 0.04815124720335007, -0.02019008807837963, 0.08392775803804398, 0.23403586447238922, 0.012863824144005775, 0.07897159457206726, 0.013927158899605274, 0.11811161786317825, -0.04406759887933731, 0.06745826452970505, -0.0133344242349267, 0.1112169697880745, 0.1027834489941597, -0.04304329678416252, -0.15943220257759094, -0.059775181114673615, -0.1725800335407257, -0.09640137106180191, 0.04914115369319916, -0.01236062590032816, -0.05757426470518112, -0.07431445270776749, -0.12762820720672607, -0.014877161011099815, -0.09797923266887665, -0.13243533670902252, -0.046598855406045914, 0.13005515933036804, -0.026331763714551926, -0.09080085903406143, -0.08576143532991409, -0.06171349808573723, -0.10952582210302353, 0.0907333493232727, 0.11398487538099289, -0.006078613456338644, 0.07276757806539536, -0.027878105640411377, -0.17858964204788208, -0.06622356921434402, 0.010416326113045216, -0.1594913899898529, -0.040875013917684555, 0.06686418503522873, 0.12419666349887848, 0.13699479401111603, -0.18956619501113892, -0.035521842539310455, 0.00428294762969017, 0.1032135933637619, -0.14686928689479828, 0.030482886359095573, -0.16295009851455688, -0.13865463435649872, -0.007800839841365814, 0.09816130995750427, -0.013939045369625092, -0.09887386858463287, 0.10719111561775208, 0.007841463200747967, 0.05887976288795471, 0.0186017993837595, -0.05475999414920807, -0.03591516241431236, -0.019414417445659637, 0.017284145578742027, 0.0804525762796402, -0.1190604418516159, -0.04185981675982475, 0.1037571057677269, 0.07412853837013245, 0.08832211047410965, 0.11456930637359619, -0.02393876016139984, 0.10081295669078827, -0.05541933327913284, -0.015358745120465755, 0.0628938376903534, 0.08105616271495819, -0.012422543950378895, 0.017661279067397118, -0.12508060038089752, 0.013125642202794552, 0.10434556007385254, 0.10607453435659409, 0.06793829798698425, 0.19910933077335358, 0.08776535838842392, -0.04566362872719765, 0.000718658440746367, 0.15483945608139038, 0.012572241015732288, -0.10654788464307785, 0.00544061278924346, -0.03389182686805725, -0.0028964851517230272, -0.01665642112493515, -0.0587153397500515, -0.08908629417419434, -0.054757196456193924, -0.016926169395446777, -0.18888269364833832, 0.09025648981332779, -0.10067995637655258, 0.08154109865427017, 0.014755677431821823, -0.05844920501112938, 0.0563412569463253, -0.02207043021917343, -0.07084107398986816, -0.1202915608882904, 0.19623413681983948, -0.09615233540534973, -0.01809825748205185, 0.23456136882305145, -0.09254425764083862, 0.11326491087675095, 0.019009524956345558, -0.1183057352900505, -0.039398327469825745, 0.09236292541027069, 0.11875734478235245, -0.2060418576002121, 1.2647408206725926e-32, -0.05870070308446884, 0.1875109225511551, -0.043660860508680344, 0.03743273764848709, -0.06538859754800797, -0.010484207421541214, -0.015785986557602882, -0.03867914155125618, -0.13628865778446198, 0.006155360955744982, -0.2133312076330185, 0.07945792376995087, -0.015342672355473042, 0.09703356772661209, 0.021121760830283165, -0.1340380609035492, -0.04588295519351959, 0.11887737363576889, -0.048394907265901566, -0.09149380773305893, 0.11592989414930344, 0.10310433059930801, -0.10047271847724915, -0.0005899773095734417, 0.03908868506550789, 0.08515673875808716, 0.02939462661743164, 0.03236014395952225, 0.04522578790783882, 0.026370780542492867, -0.043320778757333755, 0.11248106509447098, -0.02032611332833767, -0.07636227458715439, -2.1252799342619255e-05, 0.014004314318299294, -0.1375505030155182, -0.08424262702465057, -0.00439329631626606, 0.0498444065451622, 0.06513882428407669, 0.19055584073066711, -0.1245744377374649, -0.06722985208034515, 0.13485154509544373, -0.0003695887280628085, -0.23335610330104828, -0.019393721595406532, 0.04946635663509369, -0.06194109469652176, -0.032110072672367096, 0.043280038982629776, 0.02694101631641388, -0.012857453897595406, -0.016971809789538383, 0.07348262518644333, -0.11651849001646042, -0.02736712247133255, 0.05327619984745979, 0.10643436759710312, 0.0723961740732193, 0.09001193940639496, -0.04411950334906578, -0.025905059650540352, -0.12623491883277893, 0.11888601630926132, 0.012024245224893093, 0.003400312503799796, -0.1649961918592453, 0.057453643530607224, 0.06303885579109192, 0.05210387706756592, 0.1738719344139099, 0.050401341170072556, 0.16374310851097107, -0.08492141216993332, 0.019873343408107758, 0.11359991133213043, -0.002855089958757162, -0.06818030029535294, -0.0009301085956394672, 0.05310261622071266, 0.060229163616895676, 0.172726109623909, -0.03068620152771473, -0.1515510529279709, -0.051109686493873596, 0.06694228947162628, -0.03642791137099266, -0.0688091441988945, 0.1311827450990677, 0.04266886040568352, -0.1743583381175995, 0.1448613852262497, -0.14024019241333008, -1.2398848456876615e-32, -0.05027312412858009, -0.07918894290924072, 0.0032412444707006216, 0.0029574516229331493, -0.15246418118476868, 0.04420660063624382, 0.06049729138612747, 0.012383048422634602, 0.12819786369800568, -0.003930153790861368, 0.11604654788970947, 0.11692473292350769, -0.06770935654640198, -0.02548891119658947, -0.05228181555867195, -0.0389125719666481, -0.00015432141663040966, -0.032323647290468216, -0.0818772166967392, 0.03413119539618492, 0.045876286923885345, 0.15919354557991028, -0.01177296880632639, 0.13270504772663116, 0.07903555780649185, 0.11253561079502106, 0.06886649131774902, 0.12668779492378235, 0.007800315041095018, -0.018785160034894943, -0.13511371612548828, 0.03956695273518562, -0.13297489285469055, -0.05909253656864166, -0.010908067226409912, 0.005106024444103241, -0.02411741204559803, -0.17092669010162354, -0.06460043042898178, 0.05413569137454033, 0.09915290027856827, -0.03192049637436867, 0.04075844958424568, -0.008184561505913734, 0.10631482303142548, -0.01869741454720497, 0.009327784180641174, -0.028081029653549194, 0.08332119137048721, -0.0035568291787058115, 0.023669660091400146, 0.019381655380129814, 0.11620252579450607, -0.02346043288707733, -0.04603295400738716, -0.09433704614639282, 0.07017092406749725, -0.10858704149723053, -0.11161218583583832, -0.03717977553606033, 0.045517198741436005, 0.10626048594713211, 0.07421547919511795, 0.03792589157819748, -0.05834722891449928, 0.1078844740986824, 0.029816672205924988, -0.07264483720064163, 0.03696419671177864, -0.11684449017047882, -0.03665954992175102, -0.06344418227672577, 0.011129380203783512, -0.15063083171844482, -0.03994136303663254, 0.19992168247699738, 0.03700476512312889, -0.11541561782360077, -0.12047018855810165, -0.04226530343294144, -0.10950633138418198, -0.06205589324235916, 0.07160330563783646, 0.03153437748551369, -0.011130447499454021, 0.1334395408630371, -0.048235420137643814, -0.028590025380253792, -0.021585779264569283, 0.017111899331212044, -0.1325620412826538, -0.2109314650297165, -0.04531610757112503, 0.08370191603899002, -0.06045319885015488, -1.009054528822162e-07, 0.061442308127880096, 0.01481573935598135, 0.06726278364658356, -0.030146745964884758, 0.03184543922543526, 0.04361573979258537, -0.10509195178747177, 0.00512249069288373, 0.04005253314971924, 0.15139764547348022, -0.043246522545814514, 0.17648503184318542, -0.11938285082578659, -0.012445631437003613, -0.0699000358581543, 0.009902046993374825, -0.09415090829133987, -0.007044192869216204, -0.0267370343208313, -0.0727149173617363, -0.10518959164619446, 0.09741052240133286, 0.06292875111103058, -0.021605318412184715, 0.09597564488649368, -0.0007982469978742301, 0.024087613448500633, 0.002567764837294817, 0.11204932630062103, -0.023134883493185043, -0.05555329844355583, 0.0011274870485067368, 0.10388577729463577, 0.025574928149580956, 0.09174996614456177, -0.05432268977165222, 0.03505856916308403, 0.059968382120132446, 0.034249529242515564, 0.08563214540481567, -0.0054519884288311005, -0.05206143483519554, -0.04064773768186569, -0.06765622645616531, -0.015303494408726692, -0.14798887073993683, -0.10230390727519989, -0.06294572353363037, 0.10094992071390152, -0.15757371485233307, 0.0776209607720375, -0.07139313966035843, -0.03361022099852562, -0.025211568921804428, -0.04670285806059837, 0.09241542220115662, -0.13555695116519928, -0.04453028365969658, -0.06399516761302948, -0.009842166677117348, 0.0561111718416214, -0.22972668707370758, -0.001966004027053714, 0.1757786124944687], "changes": {"1wk": -8.333331326442957, "1mo": -30.050506205987386}}, {"text": "Aclaris Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update Aclaris Therapeutics, Inc. Wed, Nov 6, 2024, 3:00 PM 9 min read In This Article: ACRS -3.23% Aclaris Therapeutics, Inc. \u2013\u00a0First Patient Dosed in ATI-2138 Phase 2a Trial in Atopic Dermatitis As Previously Announced; Top-line Data Anticipated in First Half of 2025 \u2013 WAYNE, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the third quarter of 2024 and provided a corporate update. \"The third quarter of 2024 marked an important milestone for Aclaris with the dosing of our first patient in the Phase 2a trial of ATI-2138 for moderate to severe atopic dermatitis,\" said Dr. Neal Walker, Interim President & CEO and Chair of the Board of Directors of Aclaris. \"This milestone, combined with our robust financial position, underscores our commitment to executing a capital-efficient development strategy.\" Research and Development Highlights: ITK Inhibitor Programs ATI-2138 , an investigational oral covalent ITK/JAK3 inhibitor Atopic Dermatitis (ATI-2138-AD-201) : This Phase 2a open-label trial to investigate the safety, tolerability, pharmacokinetics, efficacy, and pharmacodynamics of ATI-2138 in patients with moderate to severe atopic dermatitis (AD) is ongoing. Aclaris continues to expect top-line data in the first half of 2025. ITK Selective Compound Aclaris is progressing a second generation ITK selective inhibitor to development candidate selection for autoimmune indications. Lepzacitinib ( ATI-1777) , an investigational topical \u201csoft\u201d JAK 1/3 inhibitor In January 2024, Aclaris reported positive top-line results from its Phase 2b trial of lepzacitinib in AD. Aclaris is currently seeking a global development and commercialization partner for this program (excluding Greater China). As previously announced, in 2022 Aclaris granted Pediatrix Therapeutics exclusive rights to develop and commercialize lepzacitinib in Greater China. Zunsemetinib (ATI-450) , an investigational oral small molecule MK2 inhibitor Aclaris plans to support Washington University in St. Louis in its investigator-initiated Phase 1b/2 trials of zunsemetinib as a potential treatment for pancreatic cancer and metastatic breast cancer. Aclaris expects these trials to be primarily funded by grants awarded to Washington University. Financial Highlights: Liquidity and Capital Resources As of September 30, 2024, Aclaris had aggregate cash, cash equivalents and marketable securities of $173.4 million compared to $181.9 million as of December 31, 2023. Aclaris anticipates that its cash, cash equivalents and marketable securities as of September 30, 2024 will be sufficient to fund its operations into 2028, without giving effect to any potential business development transactions, financing activities or the outcome of its strategic review. Story Continues Financial Results Third Quarter 2024 Net loss was $7.6 million for the third quarter of 2024 compared to $29.3 million for the third quarter of 2023. Total revenue was $4.3 million for the third quarter of 2024 compared to $9.3 million for the third quarter of 2023. The decrease was primarily driven by higher milestones earned during the prior year period compared to the current year period. Research and development (R&D) expenses were $6.0 million for the quarter ended September 30, 2024 compared to $23.9 million for the prior year period. The $17.9 million decrease was primarily the result of: Zunsemetinib development expenses associated with clinical trials in 2023, and drug candidate manufacturing costs; Costs associated with lepzacitinib preclinical development activities and a Phase 2b clinical trial for AD which was completed in January 2024; ATI-2138 development expenses, including costs associated with a Phase 1 multiple ascending dose (MAD) trial which was completed in September 2023 and other preclinical activities, which were partially offset by clinical development expenses associated with a Phase 2a clinical trial which commenced in August 2024; and Lower compensation-related expenses due to a decrease in headcount and higher forfeiture credits. General and administrative (G&A) expenses were $5.7 million for the quarter ended September 30, 2024 compared to $7.1 million for the corresponding prior year period. The decrease was primarily due to a reduction in compensation-related expenses due to lower headcount and higher forfeiture credits. Licensing expenses were $1.8 million for the quarter ended September 30, 2024 compared to $7.3 million for the corresponding prior year period. The decrease was primarily due to higher milestones earned during the prior year period compared to the current year period. Revaluation of contingent consideration resulted in a $0.8 million loss for the quarter ended September 30, 2024 compared to a loss of $1.7 million for the prior year period. Year-to-date 2024 Net loss was $35.5 million for the nine months ended September 30, 2024 compared to $87.0 million for the nine months ended September 30, 2023. Total revenue was $9.5 million for the nine months ended September 30, 2024 compared to $13.7 million for the nine months ended September 30, 2023. The decrease was primarily driven by higher milestones earned during the prior year period compared to the current year period. R&D expenses were $24.6 million for the nine months ended September 30, 2024 compared to $71.7 million for the corresponding prior year period. The $47.1 million decrease was primarily the result of: Zunsemetinib development expenses associated with clinical trials in 2023, and drug candidate manufacturing costs; Costs associated with lepzacitinib preclinical development activities and a Phase 2b clinical trial for AD which was completed in January 2024; ATI-2138 development expenses, including costs associated with a Phase 1 MAD trial which was completed in September 2023 and other preclinical activities, which were partially offset by clinical development expenses associated with a Phase 2a clinical trial which commenced in August 2024; and Lower compensation-related expenses due to a decrease in headcount and higher forfeiture credits. G&A expenses were $17.2 million for the nine months ended September 30, 2024 compared to $24.2 million for the prior year period. The decrease was primarily due to a reduction in compensation-related expenses due to lower headcount and higher forfeiture credits and the recognition of bad debt expense recorded in the prior year period from Aclaris\u2019 determination that collection of amounts due from EPI Health are uncertain as a result of their filing for Chapter 11 bankruptcy protection. Licensing expenses were $4.1 million for the nine months ended September 30, 2024 compared to $9.0 million for the prior year period. The decrease was primarily due to higher milestones earned during the prior year period compared to the current year period. Revaluation of contingent consideration resulted in a $3.8 million loss for the nine months ended September 30, 2024 compared to a gain of $0.6 million for the corresponding prior year period. About Aclaris Therapeutics, Inc. Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulation. For additional information, please visit www.aclaristx.com. Cautionary Note Regarding Forward-Looking Statements Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as \u201canticipate,\u201d \u201cbelieve,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cwill,\u201d and similar expressions, and are based on Aclaris\u2019 current beliefs and expectations. These forward-looking statements include expectations regarding its plans for its development programs, including its plans to seek a development and commercialization partner for lepzacitinib, the clinical development of ATI-2138, including the timing of top-line data, its plan to support Washington University in St. Louis in its investigator-initiated Phase 1b/2 trials of zunsemetinib, the sufficiency of its cash, cash equivalents and marketable securities to fund its operations into 2028, as well as its strategic review. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials, Aclaris\u2019 reliance on third parties over which it may not always have full control, Aclaris\u2019 ability to enter into strategic partnerships on commercially reasonable terms, the uncertainty regarding the macroeconomic environment and other risks and uncertainties that are described in the Risk Factors section of Aclaris\u2019 Annual Report on Form 10-K for the year ended December 31, 2023, and other filings Aclaris makes with the U.S. Securities and Exchange Commission from time to time. These documents are available under the \u201cSEC Filings\u201d page of the \u201cInvestors\u201d section of Aclaris\u2019 website at www.aclaristx.com. Any forward-looking statements speak only as of the date of this press release and are based on information available to Aclaris as of the date of this release, and Aclaris assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise. Aclaris Therapeutics, Inc. Condensed Consolidated Statements of Operations (unaudited, in thousands, except share and per share data) Three\u00a0Months\u00a0Ended Nine\u00a0Months\u00a0Ended September\u00a030, September\u00a030, 2024 2023 2024 2023 Revenues: Contract research $ 645 $ 705 $ 1,926 $ 2,469 Licensing 3,701 8,577 7,583 11,210 Total revenue 4,346 9,282 9,509 13,679 Costs and expenses: Cost of revenue (1) 654 848 2,087 2,698 Research and development (1) 5,956 23,876 24,560 71,738 General and administrative (1) 5,653 7,091 17,249 24,198 Licensing 1,754 7,344 4,070 8,955 Revaluation of contingent consideration 800 1,700 3,800 (600 ) Total costs and expenses 14,817 40,859 51,766 106,989 Loss from operations (10,471 ) (31,577 ) (42,257 ) (93,310 ) Other income: Interest income 1,991 2,316 5,850 6,320 Non-cash royalty income 894 \u2014 894 \u2014 Total other income 2,885 2,316 6,744 6,320 Net loss $ (7,586 ) $ (29,261 ) $ (35,513 ) $ (86,990 ) Net loss per share, basic and diluted $ (0.11 ) $ (0.41 ) $ (0.50 ) $ (1.25 ) Weighted average common shares outstanding, basic and diluted 71,381,731 70,807,934 71,249,813 69,452,495 (1) Amounts include stock-based compensation expense as follows: Cost of revenue $ 232 $ 347 $ 707 $ 1,119 Research and development 1,124 3,072 2,192 9,168 General and administrative 1,648 2,529 5,097 8,989 Total stock-based compensation expense $ 3,004 $ 5,948 $ 7,996 $ 19,276 Aclaris Therapeutics, Inc. Selected Consolidated Balance Sheet Data (unaudited, in thousands, except share data) September 30, 2024 December 31, 2023 Cash, cash equivalents and marketable securities $ 173,436 $ 181,877 Total assets $ 182,394 $ 197,405 Total current liabilities $ 18,816 $ 30,952 Total liabilities $ 52,243 $ 40,226 Total stockholders\u2019 equity $ 130,151 $ 157,179 Common stock outstanding 71,417,513 70,894,889 Aclaris Therapeutics, Inc. Selected Consolidated Cash Flow Data (unaudited, in thousands) Nine Months Ended Nine Months Ended September 30, 2024 September 30, 2023 Net loss $ (35,513 ) $ (86,990 ) Depreciation and amortization 664 635 Stock-based compensation expense 7,996 19,276 Revaluation of contingent consideration 3,800 (600 ) Changes in operating assets and liabilities 11,916 (3,885 ) Net cash used in operating activities $ (11,137 ) $ (71,564 ) Aclaris Therapeutics Contact: investors@aclaristx.com View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "ACRS", "date": "2024-11-06T15:00:00", "sentiment": {"score": 0.650388402864337, "confidence": 0.6592162251472473, "probabilities": {"positive": 0.6592162251472473, "negative": 0.008827822282910347, "neutral": 0.33195599913597107}}, "embedding": [-0.2647450268268585, -0.004900309257209301, -0.08428893983364105, -0.06301358342170715, 0.06394608318805695, -0.054806023836135864, -0.11709247529506683, 0.3425041437149048, 0.0402168370783329, 0.07846858352422714, -0.03765765577554703, -0.009535693563520908, 0.07180765271186829, 0.13936281204223633, -0.07488852739334106, 0.14636662602424622, 0.09293925762176514, 0.050566405057907104, -0.11180730909109116, -0.09004274010658264, -0.021225586533546448, 0.010312305763363838, 0.010664619505405426, -0.05524590611457825, -0.12477409839630127, -0.05802304297685623, -0.07885338366031647, -0.05146840214729309, -0.21329522132873535, -0.031113460659980774, 0.06601615995168686, 0.04780953750014305, 0.09424900263547897, -0.032177992165088654, -0.04733859375119209, 0.010634582489728928, -0.1660165935754776, -0.04284404218196869, 0.09353797882795334, -0.07318796962499619, -0.003364969976246357, -0.049865175038576126, -0.10469362139701843, 0.008689556270837784, 0.0576174221932888, -0.21131616830825806, -0.1725769340991974, 0.06111489236354828, 0.04259197413921356, 0.21605335175991058, -0.10622811317443848, -0.019479116424918175, 0.10457116365432739, 0.029647357761859894, -0.20783282816410065, 0.006860925815999508, -0.2741815447807312, -0.061395883560180664, -0.056636154651641846, 0.11047618836164474, -0.09573633223772049, -0.22639018297195435, 0.03965263441205025, 0.014335385523736477, 0.04444175958633423, -0.018486449494957924, 0.059442199766635895, -0.04050130769610405, -0.010573260486125946, 0.07087011635303497, -0.058908551931381226, -0.06520634144544601, 0.05639306828379631, 0.1897364854812622, 0.09300577640533447, 0.045835524797439575, 0.054324112832546234, 0.09716682136058807, 0.06610732525587082, -0.21796035766601562, 0.0451883040368557, -0.0047059375792741776, 0.09092049300670624, 0.08306968212127686, -0.054125040769577026, -0.025439918041229248, -0.021641630679368973, 0.12507036328315735, 0.06225976347923279, 0.11515955626964569, 0.20037426054477692, 0.06360939145088196, -0.020798463374376297, 0.023100586608052254, 0.0895800068974495, 0.017183560878038406, -0.009415975771844387, 0.015791170299053192, 0.01860564574599266, -0.0021964767947793007, -0.04323258250951767, -0.08432944118976593, -0.08939052373170853, -0.1033329963684082, 0.006641739048063755, -0.21154221892356873, 0.1107739806175232, -0.16252899169921875, 0.04580565541982651, 0.016654927283525467, -0.08029346913099289, -0.03506261855363846, -0.017443448305130005, -0.11372779309749603, -0.009837261401116848, 0.2004213035106659, 0.03780517727136612, -0.009142044931650162, 0.2815643846988678, -0.08511431515216827, 0.1377638280391693, 0.013966974802315235, -0.0968875139951706, -0.11153110861778259, 0.06729676574468613, 0.08822957426309586, -0.09111446142196655, 6.092472609612711e-33, -0.15073516964912415, 0.13283610343933105, -0.037310633808374405, 0.034245673567056656, -0.10435128211975098, -0.044888246804475784, 0.06064456328749657, 0.10937777161598206, -0.1745496243238449, -0.05400495231151581, -0.2344018816947937, 0.0023321621119976044, 0.00546624418348074, 0.11466588079929352, 0.007521991617977619, -0.14974990487098694, 0.19060903787612915, 0.03041979670524597, -0.077529177069664, -0.09627513587474823, 0.12179826200008392, -0.016195490956306458, -0.02797635644674301, 0.07920682430267334, -0.11346332728862762, 0.1709432154893875, 0.1382589042186737, 0.02984372153878212, 0.04262949526309967, -0.008161177858710289, -0.07655118405818939, 0.1266355812549591, -0.028911979869008064, 0.02249240130186081, 0.016079597175121307, 0.05992180109024048, -0.08531135320663452, -0.029786262661218643, 0.06620567291975021, 0.05483284592628479, 0.03854691982269287, 0.09878711402416229, -0.14403793215751648, -0.08470765501260757, 0.09556139260530472, 0.0029612230136990547, -0.19555960595607758, 0.08431903272867203, 0.030568335205316544, -0.0332641564309597, 0.0457465834915638, -0.015195385552942753, 0.0006949398666620255, -0.015541665256023407, -0.007856810465455055, 0.1270056515932083, -0.18835501372814178, -0.024564247578382492, 0.13431549072265625, -0.0015592701965942979, 0.05797892063856125, -0.04136211425065994, -0.057048872113227844, 0.12062092125415802, -0.09959988296031952, 0.15315911173820496, -0.04664791375398636, -0.10815314203500748, -0.1339612901210785, 0.147807314991951, 0.016045304015278816, 0.09217658638954163, 0.1490272879600525, 0.19068264961242676, 0.2158982753753662, -0.024475352838635445, 0.14200374484062195, 0.1443253606557846, -0.041404418647289276, 0.08459392189979553, -0.02724006585776806, 0.12344422936439514, 0.0012986082583665848, 0.11735087633132935, -0.04243488982319832, -0.11657083034515381, -0.04403434693813324, 0.1429455280303955, -0.06875481456518173, -0.05335172638297081, 0.18468134105205536, 0.003342595649883151, -0.0747372955083847, 0.23050877451896667, 0.02704617753624916, -8.773396861594178e-33, 0.06000201031565666, -0.04590963199734688, -0.09343864023685455, -0.10280749201774597, -0.07726969569921494, 0.21373969316482544, 0.0674012154340744, 0.07702701538801193, 0.19065582752227783, -0.039901308715343475, 0.16479617357254028, 0.08814762532711029, -0.0004952577874064445, -0.13620500266551971, -0.09210722148418427, 0.18393664062023163, -0.02761376090347767, -0.036298833787441254, -0.10693733394145966, 0.09937866777181625, 0.011441439390182495, 0.13535694777965546, 0.07770000398159027, 0.002444487065076828, 0.07290074229240417, -0.025934111326932907, 0.10156548023223877, 0.03854379802942276, -0.017456497997045517, 0.047052934765815735, -0.08131945133209229, -0.061751604080200195, -0.2265612930059433, -0.01755986548960209, -0.04812370240688324, -0.13066259026527405, -0.03730930760502815, -0.24594877660274506, -0.14331810176372528, -0.07176107913255692, 0.031289685517549515, -0.0853891521692276, -0.022255871444940567, 0.07313154637813568, 0.12256958335638046, 0.050560176372528076, -7.295049726963043e-05, 0.005499107297509909, 0.025089526548981667, -0.1780756413936615, 0.00729496031999588, -0.023704122751951218, 0.1223687082529068, -0.09037540853023529, 0.06474912911653519, 0.03427698463201523, 0.0788550078868866, -0.12151774764060974, -0.04724209010601044, -0.0376264825463295, 0.0027920452412217855, 0.014257878065109253, 0.05489351600408554, 0.012910500168800354, -0.004376016557216644, 0.11835332214832306, 0.057299647480249405, -0.09869483858346939, 0.07239746302366257, -0.08488961309194565, 0.01899028941988945, -0.03749901056289673, -0.18466386198997498, -0.14898310601711273, -0.025212574750185013, 0.1307855248451233, -0.0355619341135025, -0.11607501655817032, -0.19471997022628784, -0.054744333028793335, -0.08268798887729645, -0.005527213215827942, 0.025709940120577812, 0.045099373906850815, -0.010866302996873856, 0.01005852036178112, 0.03738055378198624, 0.019492391496896744, -0.023256555199623108, 0.03365267068147659, -0.10391519963741302, -0.016765983775258064, -0.12493594735860825, 0.22193381190299988, -0.045058269053697586, -1.0089182467254432e-07, 0.1735357642173767, -0.03729953244328499, 0.029004115611314774, -0.11441309750080109, -0.07779863476753235, 0.06641844660043716, -0.11628501117229462, 0.006067243404686451, -0.008767504245042801, 0.010893527418375015, -0.13948313891887665, 0.18643777072429657, -0.007218482438474894, 0.024111375212669373, -0.15096735954284668, -0.021431967616081238, 0.08366991579532623, 0.09533941745758057, 0.01874341070652008, 0.019526420161128044, -0.14226341247558594, 0.011394749395549297, 0.08705894649028778, -0.11846451461315155, 0.11558107286691666, -0.049980487674474716, -0.02334548346698284, 0.0634666308760643, 0.0832141637802124, -0.11746586859226227, -0.0826699286699295, 0.023055914789438248, 0.05163145810365677, -0.012141287326812744, 0.026327624917030334, -0.0492611862719059, -0.008265536278486252, -0.03814070671796799, 0.0995408147573471, 0.08690311014652252, 0.0851963609457016, 0.02347302809357643, 0.02027583122253418, 0.03988727554678917, -0.04431844875216484, -0.16373352706432343, -0.04733584448695183, -0.17172512412071228, 0.03914400562644005, -0.19676053524017334, -0.020148951560258865, 0.03995262831449509, -0.07180231064558029, -0.08773371577262878, 0.0188276544213295, 0.11087314784526825, -0.04664546996355057, -0.2154509276151657, -0.061654698103666306, -0.15132541954517365, 0.07259683310985565, -0.1830732524394989, -0.026593592017889023, 0.15483951568603516], "changes": {"1wk": 13.274334229301918, "1mo": 68.58406897597216}}]